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Obesity is associated with pro-inflammatory changes within adipose tissue which 
are mechanistically linked to the development of cardiometabolic disease. Currently, little 
is known regarding whether weight loss resolves obesity-induced changes including 
adipose tissue inflammation. We sought to clarify unresolved mechanisms that control 
adipose tissue leukocyte dynamics and metabolic dysfunction during obesity, weight loss, 
and weight regain. We first identified CD64 as a better marker than what has been 
previously used for identifying adipose tissue macrophages in mice. Use of this marker 
allows the definitive identification of macrophages from dendritic cells within adipose 
tissue and resolves controversies in the field regarding this population. Obesity was 
induced using a high-fat diet (60% kcal derived from fat) for 12 weeks and weight loss 
was achieved by switching animals back to normal diet (13.5% kcal derived from fat) for 
an additional 8-24 weeks. We show that even a prolonged six-month weight loss cycle in 
mice fails to completely resolve obesity-induced adipose tissue macrophage activation 
which may contribute to the persistent adipose tissue damage and reduced insulin 
sensitivity observed in formerly obese mice. Finally, we investigated if unique metabolic 
abnormalities develop in formerly obese mice upon HFD re-challenge for an additional 6 
weeks. Weight regain was associated with impaired adipose tissue expansion, 
hyperinsulinemia, hepatic steatosis and elevated serum transaminase concentrations. We 
conclude that obesity imparts a lasting impact on adipose tissue immune and metabolic 
function that persists despite weight loss and may have long-term negative effects on 
health. As a result, weight regain in formerly obese mice is accompanied by hastened 





Chapter 1 – Introduction 
 
This dissertation describes three projects undertaken in an attempt to resolve 
several unanswered questions regarding adipose tissue leukocyte dynamics and metabolic 
perturbations during obesity, weight loss, and weight regain. The following introduction 
will briefly outline relevant background material and highlight aspects of what is known 
and unknown regarding insulin resistance development with obesity. I will provide 
working definitions for obesity and hyperglycemia, detail the importance of adipose 
distribution, and highlight comorbidities associated with obesity which are most pertinent 
for this dissertation. I will then introduce our mouse model of obesity and describe what 
is known regarding the involvement of obesity-associated inflammation in establishing 
insulin resistance in both rodents and humans. Finally, I will provide specific background 
information helpful for understanding the context, motivations, and objectives for 




Obesity is increasingly recognized as a worldwide public health issue over the last 
few decades. Obesity is known as a major risk factor for the development of severe 
metabolic disorders including type 2 diabetes and cardiovascular disease. Before delving 
into the complexities of obesity-induced physiological changes, it’s critical to provide 
clear definitions. Obesity is a condition of excessive fat accumulation, typically in 
adipose tissue. There are a number of techniques capable of accurately measuring body 
fat accumulation in vivo including densitometry, magnetic resonance imaging and dual-
energy X-ray absorptiometry (1). These methods calculate body fat as a percent of total 
body weight. Obesity is typically defined as ≥ 25% fat mass in men and ≥ 30% fat mass 
in women (2-4). While these methods are useful for precise measurement of fat mass, 
2 
 
they are often only used for research purposes and not widely-used in clinical practice. 
Instead, body weight and body mass index (BMI), weight in kilograms divided by height 
in meters squared, are the most commonly used assessments for determining overweight 
and obesity in humans due to simplicity and cost efficiency (1). The World Health 
Organization has determined various BMI cutoff values to determine weight 
classifications based on comorbidities risk associated with a given BMI range (Table 1) 
(5; 6). Unfortunately, the diagnostic accuracy of BMI as an assessment of adiposity is 
known to be limited and unreliable in certain subjects making BMI a useful screening 
tool for obesity but a poor measure of percent body fat. A systematic review of the 
literature comparing BMI with body fat percent revealed the commonly used BMI cutoff 
value of 30 tends to have high specificity but low sensitivity for identifying obesity (3). 
So while more than 95% of subjects with BMI values ≥ 30 kg/m
2
 can also be defined as 
obese by body fat percent, more than half of people with excess adiposity may be missed 
using a BMI cutoff value of ≥ 30 kg/m
2
 (7; 8).  
 
Table 1 – Classification of obesity and comorbidity risk in adults. Recreated from 
Ruth Chan and Jean Woo 2010 (6). 
Classification BMI Co-morbidity Risk 
Underweight <18.5 Low 
Normal Weight 18.5-24.9 Low 
Overweight 25.0-29.9 Increased 
Obese Class I 30.0-24.9 Moderate 
Obese Class II 35.0-39.9 Severe 
Obese Class III >40.0 Very Severe 
 
Distribution of adiposity 
Fat distribution is just as critical of a determinant for overall cardiometabolic risk 
as adiposity and BMI. Excess visceral intra-abdominal, or central fat, is associated with 
increased metabolic disease risk (9). Waist circumference is often used as a surrogate 
marker of central adiposity due to the higher costs associated with more precise body 
3 
 
composition measurement techniques. Waist circumference and BMI are highly 
correlated; waist measures in men and women > 102 cm and > 89 cm, respectively, are 
associated with an overall BMI of ≥ 30 kg/m
2
 and increased cardiometabolic disease risk 
(9-11). Waist circumference measures both subcutaneous and visceral adipose tissue 
mass and therefore cannot distinguish which fat depot is associated with increased 
cardiometabolic risk. The general consensus is that visceral adipose tissue expansion, 
rather than subcutaneous, is associated with increased risk for development of metabolic 
disorders. Visceral adipose tissue expansion is associated with ectopic fat deposition in 
liver and muscle tissue while subcutaneous adipose expansion is not (12; 13). Several 
hypotheses have been proposed to explain this phenomena; one model suggests that 
obesity-associated dysfunction in adipose tissue may eventually limit its lipid storage 
capacity. The result is that excess lipid begins to “spill over” into other metabolically 
relevant organs thus increasing fat deposition in liver, muscle tissue and kidneys (14). 
Ectopic lipid accumulation and lipotoxicity is correlated with increased insulin resistance 
and cardiometabolic disease development (15-18). Obesity and metabolic dysfunction is 
also associated with increased circulating markers of inflammation. Visceral, but not 
subcutaneous, adipose tissue is a major source of circulating inflammatory cytokines 
during obesity in both humans and mice (19-22). Rodent visceral gonadal white adipose 
tissue depot is therefore used as a murine equivalent of human visceral omental tissue due 
to similarities in gene expression and obesity-associated inflammation (23). In male mice 
this depot is termed the epididymal white adipose tissue depot (eWAT). The use of 
rodent models of obesity will be discussed in more detail below. 
 
Epidemiology of Obesity 
The prevalence of obesity increased dramatically worldwide within the last few 
decades. The National Health and Nutrition Examination Survey (NHANES) is a cross-
sectional study of the health and nutritional status of both children and adults in the 
United States conducted by the Center for Disease Control and Prevention. According to 
NHANES data, the overall prevalence of obesity, defined by BMI, in the U.S. during 
2011-2014 was 36.5% in adults and 17.0% in youths between 2-19 years of age (24). 
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Obesity prevalence was highest among adults age 40-59 years at 40.2% and dropped to 
37.0% in adults age 60 years and over. Obesity rates were slightly higher among women 
(38.3%) than men (34.3%). Prevalence rates change depending on ethnicity and were 
lowest among Asian adults (11.7%) and highest among non-Hispanic black (48.1%) and 
Hispanic populations (42.5%). Obesity prevalence among Non-Hispanic white 
populations was 34.5%. More alarmingly, the overall trend for both adult and youth 
populations suggest obesity rates continually increased between 1999 and 2014. A 
systematic review estimated the number of overweight or obese individuals worldwide 
was over 2.1 billion in 2013 and found that prevalence has increased substantially over 
the past three decades (25). Increases were seen in both developed and developing 
countries with no country showing declines within this timeframe.  
There is a substantial cost, both economic and health, associated with obesity. A 
systematic review estimated that the direct medical cost of overweight and obesity in the 
U.S. equated to between 5% and 10% of total healthcare spending  (26). The primary 
concerns with rising obesity rates are the substantially elevated risks for development of 
life-threatening comorbidities.  
 
Comorbidities Associated with Obesity 
Obesity substantially increases morbidity and mortality among older adults in 
large part due to the increased risk for development of chronic diseases including, but not 
limited to, type 2 diabetes mellitus, cardiovascular disease, cancer, hypertension, and 
sleep apnea (27-30). The risk of death is increased by as much as 3-fold in obese subjects 
compared to normal-weight individuals (28). For the purposes of this dissertation, I will 
focus on discussing the mechanisms by which obesity contributes to the development of 
insulin resistance, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) 
development. 
 
Insulin Resistance and Type 2 Diabetes 
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Insulin resistance refers to the inability of cells to properly respond to insulin 
resulting in dysregulated glucose metabolism. One of the more prominent consequences 
of insulin resistance is reduced glucose uptake by cells in muscle, liver, and fat to a given 
amount of insulin leading to chronically elevated plasma glucose levels. Pancreatic beta 
cells increase insulin production in an attempt to maintain blood glucose within a normal 
range. Failure to produce sufficient quantities of insulin leads to hyperglycemia and the 
development of type 2 diabetes. There are a few measures of measuring glycemic control 
and insulin resistance which are all related but have subtle diagnostic differences. One of 
the most common is fasting blood glucose where blood or plasma glucose levels are 
measured after a period of fasting for 6-8 hours which is the time needed to reach a 
natural lower plateau for blood insulin and glucose. Humans can be considered to have 
impaired fasting blood glucose levels between 100 mg/dl and 125 mg/dl and diabetes as 
≥126 mg/dl (31; 32). Glucose tolerance tests are also commonly used diagnostic tools 
whereby a glucose load is provided to fasted patients and blood glucose is then measured 
up to two hours later. Using a glucose tolerance test, type 2 diabetes can be defined as a 
2-hour blood glucose level in excess of 200 mg/dl following oral glucose administration 
(32). Hemoglobin A1c levels, also known as glycated hemoglobin, are also a commonly 
used diagnostic tool which provides a marker for average blood glucose levels over the 
past 2-3 months. High blood glucose increases the percent of glycated hemoglobin 
throughout the 2-3 month life span of red blood cells. As a result, variables that affect 
blood cell survival can also affect glycated hemoglobin levels irrespective of actual blood 
glucose levels (33). Nevertheless, it can be useful for tracking long-term glycemic control 
in patients with diabetes being defined as ≥6.5% and normal glycated hemoglobin ranges 
falling below 6.0% (32). While I will primarily focus on insulin’s role in glycemic 
control, it’s important to note that insulin is a multi-purpose hormone. As a result, insulin 
resistance also results in disruption to a number of metabolic pathways including 
carbohydrate metabolism, lipid metabolism, and protein production (34). 
Individuals with higher BMI have increasingly higher risk for the development of 
type 2 diabetes. A recent study using the electronic health records system found that a 
BMI of 30-35 kg/m
2 
increased a subject’s relative risk ratio for diabetes development by 
2.5 and a BMI of ≥40 kg/m
2 
increased relative risk to 5.1 compared to normal weight 
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subjects (35). The World Health Organization has criteria to define normoglycemia (≤ 
106 mg/dl), prediabetes (between 106 mg/dl and 126 mg/dl) and diabetes (≥126 mg/dl). 
Using these criteria, Ligthart et al. found that the lifetime risk for diabetes development 
in patients aged 45 years with prediabetes to be 74%, suggesting substantial risk for 
eventual type 2 diabetes development once insulin resistance has started (36). 
 
Non-alcoholic Fatty Liver Disease Development 
Non-alcoholic fatty liver disease is also strongly correlated with obesity and 
insulin resistance. Between 84% and 96% of patients undergoing bariatric surgery present 
with NAFLD (37). Between 25% and 55% of these patients have progressed to the more 
severe nonalcoholic steatohepatitis state, characterized by hepatic inflammation, and 
between 34% and 47% have developed hepatic fibrosis. Advanced stages of NAFLD are 
associated with liver damage, cirrhosis, liver failure, and hepatocellular carcinoma (37; 
38). NAFLD is also intimately connected with insulin resistance and metabolic 
syndrome. Hepatic insulin resistance is observed in many cases of NAFLD and is 
associated with obesity and type 2 diabetes (39-41). Several publications suggest that 
NAFLD causes systemic insulin resistance (42), but this remains an open question in the 
field as others assert that hepatic steatosis is not sufficient to cause insulin resistance (43). 
Regardless, the literature clearly shows NAFLD is a common and pertinent disease 
feature in patients presenting with obesity and metabolic syndrome. The association of 
NAFLD with obesity and insulin resistance highlights the range of physiological 
consequences incurred with excess adiposity. 
 
Murine Models of Obesity 
A number of rodent models for obesity exist and are widely used by researchers to 
investigate obesity-induced insulin resistance and cardiometabolic disease development. 
Spontaneous mutations in the C57BL/6 strain led to the discovery of the well-known 
leptin-deficient (Lep
ob/ob
) and leptin receptor-deficient (LepR
db/db
) mice which represent 
genetic models of obesity development as leptin deficiency causes hyperphagia which 
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leads to excessive weight gain starting between 3-4 weeks of age in mice. These mice can 
grow in excess of 100g total body weight and develop insulin resistance. Despite 
widespread use, the leptin deficient model also introduces experimental artifacts which 
can confound results. Leptin is a highly conserved hormone that is both structurally and 
functionally similar to the cytokine interleukin 6 (IL-6). As a result, leptin influences 
systemic innate and adaptive immune responses (44). For example, leptin deficient mice 
are resistant to both actively and passively induced experimental autoimmune 
encephalomyelitis with reduced proliferative responses to introduced antigens (45). This 
limits the potential utility of the leptin deficient mouse model when investigating the 
association of inflammation with obesity and insulin resistance. In addition, while the 
heritability of obesity appears to be high in humans, monogenic mutations leading to 
human obesity are rare (46; 47).  
Our laboratory has instead adopted the use of a diet-induced obesity (DIO) model 
in mice using a hypercaloric 60% high-fat diet (HFD) which is fed ad libitum for 10-20 
weeks (48-51). This model was designed to better represent conditions leading to obesity 
development in humans due to caloric excess. The pharmacologic predictive validity of 
this model is good; DIO rats and mice are responsive to anti-obesity drugs found 
effective in humans including glucagon-like peptide-1 receptor agonists, sibutramine, and 
contrave (52-55). Several higher-fat diet variants are available and have been used by 
researchers worldwide for decades. One of the common HFD formulations was 
developed by Research Diets Inc. in 1996 at the request of an investigator who required a 
defined diet product. This HFD formula contained a caloric energy contribution of 20% 
from protein, 35% from carbohydrate, and 45% from fat. For the studies presented in this 
dissertation, we used a higher fat diet with the caloric energy composition being 20% 
from protein, 20% from carbohydrate and 60% from fat. While the original 45% HFD 
was designed to more closely mimic Westernized diets in humans, both diets continue to 
be used today and there is no consensus on which is the better diet for use in mouse 
models of obesity and cardiometabolic disease. Through internal comparisons of the 
commonly available high-fat diets, we have found that the 60% HFD induces more 
consistent weight gain and insulin resistance. Guo et al. tracked body weight gain and 
weekly NMR spectroscopy measurements of body composition in mice fed a 60% HFD 
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(56). Mice fed HFD started at 26g total body weight and 7% body fat and, after 19 weeks 
HFD, increased up to ~47.5g and 41% body fat (Table 2) (56). Our data largely matches 
these observations. In our laboratory, after 20 weeks of 60% HFD an average mouse 
weighs 52.9g (± 1.69 SD) with 42.08% body fat (± 0.50 SD). An average age-matched 
normal diet fed mouse weighs 29.73g (± 0.11 SD) with 17.31% body fat (± 1.46 SD). A 
body fat composition of 40% matches what might be expected in an individual with a 
BMI of approximately 40 kg/m
2 
(57). Based on these predictable body composition 
changes with HFD, we typically provide HFD for at least 12 weeks and I set a lower 
threshold of obesity as ≥40g total body weight (Table 2). 
 
Table 2 – Body fat percent in C57BL/6 male mice increases with body weight. Table created 
from body weight and body composition curves in Guo et al. 2009 (56). 
Body Weight (grams) Body Fat (%) Weeks on 60% HFD 
26 7 0 
30 16 ~1 
35 25 ~4 
40 33 ~8 
45 40 ~12 
 
The DIO model in rodents induces metabolic disorder changes consistent with 
what’s been observed in human subjects. Rodents with DIO experience hyperleptinemia, 
hyperinsulinemia and hyperglycemia similar to humans with obesity (58). Comparative 
functional genomics revealed the visceral eWAT depots of rats and mice with DIO have 
similar expression profiles as obese human adipocytes and the authors concluded the DIO 
rodent model appropriately models human obesity (23). In particular, both rodents and 
humans with obesity showed upregulation of immune response-related and angiogenesis 
genes in adipose tissue when compared to lean controls. As a result, the eWAT depot is 
generally viewed as a murine equivalent to human visceral adipose tissue (omental 
adipose depot) given the similarities in expansion, leukocyte accumulation and 
inflammation changes observed in the literature. 
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As a final note, it should be mentioned that obesity and insulin resistance 
development is not equivalent among different mouse strains. Leptin deficiency in 
BALB/cJ mice showed a 35%-40% reduction in total body weight gain and a 60% 
decrease in adipose mass. Despite reduced adiposity, BALB/cJ  mice have worse insulin 
resistance and hyperlipidemia compared to C57BL/6 mice (59). Leptin deficiency in 
FVB/N mice also worsens insulin resistance and increases blood glucose (60). This strain 
effect variation is observed in DIO rodent models as well (61; 62). There are also sex 
differences in response to HFD. Female DIO mice are resistant to weight gain and insulin 
resistance development (63). Our studies exclusively used male C57BL/6 mice, but it’s 
important to note the potential variation that exists in HFD response between strains and 
sex, and is a subject of continued investigation by the Lumeng laboratory and others.  
 
Molecular Drivers of Obesity-Associated Insulin Resistance and Inflammation 
An interesting phenomenon exists, termed metabolically healthy obesity, defined 
as the presence of obesity despite the absence of metabolic and cardiovascular disease 
(64-67). Precise definitions for this phenomenon are variable, making exact prevalence 
calculations difficult, but it’s suggested that as many as one in three subjects with obesity 
are metabolically healthy (65; 68). This is a highly contentious and hotly debated topic 
with some suggesting it’s simply a matter of time before metabolically healthy obese 
patients develop metabolic syndrome. Regardless, the data clearly indicate that while 
BMI and excess adiposity correlate strongly with cardiometabolic disease risk, there are 
additional mechanisms at play that modify actual disease development. Over the past 
decade numerous laboratories have begun to focus on inflammation as the potential 
mechanistic link between obesity and cardiometabolic disease development. 
 
Obesity-Associated Adipose Tissue Inflammation  
Over one hundred years ago, extremely high doses of sodium salicylate (upwards 
of 7.5 g/d) were found to alleviate the symptoms of diabetes mellitus, providing the first 
published evidence for the potential role of inflammation in insulin resistance (69-71). It 
wasn’t until the early 2000s that the link was established showing inhibition of nuclear 
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factor kappa-B kinase subunit beta (NF-κB), a major transcription factor important for  
regulating immune responses, was the mechanism responsible for improved metabolic 
health (72; 73). Publications from the early 1990s reinvigorated a modern day interest in 
inflammation as a potential mechanistic link between obesity and metabolic dysfunction. 
In 1993 two landmark publications identified the cytokine tumor necrosis factor (TNFα) 
as being overproduced in the adipose tissue of obese mice and, through neutralization 
studies, showed TNFα played a direct role in obesity-associated insulin resistance (74; 
75). Interest in obesity-associated inflammation has grown tremendously in recent years; 
a PubMed search for [“adipose tissue” AND inflammation] over the last twenty years 
returns approximately 7,500 publications with over 900 published per year since 2013. 
Obesity is now known to elevate production of several pro-inflammatory cytokines and 
chemokines within adipose tissue including TNF-α, IL-1β, IL-6, leptin, IL-8, CCL2, and 
MCP-1 and is associated with elevated acute-phase response proteins in serum (76-78). 
The NF-κB, c-Jun N-terminal kinase (JNK), and inflammasome pathways are all 
activated within adipose tissue of obese subjects and have been implicated in the 
development of insulin resistance (73; 79-81).  
 
Molecular Links between Inflammation and Insulin Resistance 
Inflammation-induced downstream defects of the insulin receptor signaling 
response system is hypothesized as one of the primary mechanistic links between 
inflammation and insulin resistance (Figure 1-1). Insulin binding to the insulin receptor, a 
tyrosine kinase receptor, initiates an autophosphorylation cascade on the receptor’s 
tyrosine residues. The activated insulin receptor can then further phosphorylate tyrosine 
residues on downstream signaling proteins including the insulin receptor substrate (IRS) 
family (82). Tyrosine phosphorylation of IRS proteins allows further downstream 
activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and 
mitogen-activated protein kinase pathways (82). Glucose transporter type 4 (GLUT4) 
expression on the plasma membrane of cells permits circulating glucose uptake in 
response to insulin signaling. PI3K pathway activation is known to be essential, but not 
sufficient, for rapid translocation of GLUT4 to the plasma membrane. Inflammation 
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signaling pathways, however, are capable of directly inhibiting the insulin signaling 
cascade. JNK activation can cause insulin resistance through the direct phosphorylation 
of serine residues on IRS-1 which disrupts binding and inhibits tyrosine kinase cascade 
activity (83; 84). IKKβ activity inhibits insulin signaling through activation of NF-κB and 
the production of proinflammatory cytokines such as TNFα, IL-6 and IL-1β. These 
cytokines feed back onto insulin-responsive cells thereby increasing JNK activation. In 
addition, these cytokines promote suppressor of cytokine signaling (SOCS) production 
which can also promote insulin resistance through inhibition of tyrosine phosphorylation 
on the insulin receptor and IRS proteins (85; 86).  
 
Figure 1-1 – Inhibitory effects of inflammation on insulin signaling. Under homeostatic 
conditions, insulin activates an IRS/PI3K/AKT dependent pathway to promote GLUT4 
translocation to the surface membrane. In contrast, under inflammatory conditions, TNFa-
mediated activation of JNK promotes direct inhibition of IRS through phosphorylation of serine 
residues which reduces binding efficiency and reduces tyrosine phosphorylation on IRS. 
Thereafter, activation of NFκB enhances inflammatory cytokine production which can feed back 
onto the cell to further perpetuate inhibition of downstream insulin signaling. Insulin signaling is 
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also self-regulatory, in both homeostatic and inflammatory conditions, through activation of 
mTORC1 and S6 kinase which inhibits IRS activity through serine phosphorylation.  
 
However, there is also evidence suggesting that low levels of inflammatory 
signaling, for instance TNFα, is actually necessary for optimal adipogenesis and 
adipocyte function (87). In addition, genetic models that enhance NF-κB activity can 
prevent DIO and insulin resistance due to increased energy expenditure despite increased 
systemic TNFα and IL-6 (88). Human clinical trials using TNFα antagonists have shown 
little improvement in insulin sensitivity and hyperglycemia (89-91), though it’s been 
argued the few existing studies are underpowered and that TNFα-antagonism merits more 
carefully designed investigation (92). IL-1β antagonism or neutralization in clinical trials 
has shown improvements in insulin sensitivity while reducing markers of metabolic 
syndrome, but with unknown long-term efficacy and unknown mechanism (93-95). So 
while inflammatory pathway activation can directly inhibit insulin signaling, our 
understanding of inflammation’s full involvement in insulin resistance and adipose tissue 
function is far from complete. Overall, I believe this highlights the complex and 
multifactorial nature of cardiometabolic disease development with obesity.  
 
Adipose Tissue as the Center of Obesity-Associated Inflammation 
Obesity is associated with dramatic inflammatory changes within adipose tissue 
including dramatic shifts in both innate and adaptive leukocyte populations (96; 97). A 
critical question in the field is what mechanism(s) are responsible for initiating 
inflammatory responses within adipose tissue and adipocytes during obesity. Potential 
activating pathways leading to adipose tissue inflammation during obesity include toll-
like receptor signaling, inflammasome activation, ER stress, cellular stress, adipocyte 
death, adipocyte hypoxia and increased microbial contamination just to name a few (97). 
These changes eventually encourage the recruitment and activation of pro-inflammatory 
leukocytes (97; 98). The prevailing hypothesis is that continual accumulation and 
activation of pro-inflammatory leukocytes contributes to a state of chronic low-grade 




Leukocyte Mediators of Obesity-Associated Inflammation  
Adipose tissue can be broadly separated into two main fractions including mature 
adipocytes and an inter-adipocyte stromal-vascular fraction (SVF) containing a variety of 
cells including preadipocytes, endothelial cells, and leukocytes. Both lean and obese 
adipose tissue contains a resident leukocyte population comprised of nearly the full range 
of immune cell types. Obesity causes dramatic changes in relative leukocyte population 
frequencies and activation profiles within adipose tissue. These changes are further 
complicated and compounded by the extended chronic stimulus period which can last for 
decades. The relative obesity-associated change of various leukocyte populations in 
adipose tissue is provided (Table 3). Certain leukocyte populations are associated with 
lean adipose tissue, maintenance of homeostatic function, insulin sensitivity, and low 
inflammation. These include regulatory CD4
+
 T cells (Tregs), CD4
+
 type 2 helper T cells 
(Th2), M2-like resident macrophages, eosinophils, and group 2 innate lymphoid cells (97; 
103-105). Their insulin sensitizing effects are thought to be largely due to secretion of 
type 2 cytokines including IL-4, IL-10, IL-13 and IL-33 (106). Other leukocyte 
populations are associated with obese adipose tissue and are thought to contribute to 
adipose tissue dysfunction, inflammation, and insulin resistance both locally and 
systemically. These include Th1 cells, Th17 cells, CD8
+
 cytotoxic T cells, M1-like pro-
inflammatory macrophages, dendritic cells (DC), natural killer cells (NK), B cells, and 
neutrophils (Figure 1-2) (104; 107-109). Accumulation of these leukocytes enhances 
production of pro-inflammatory cytokines including IFNγ, TNFα, IL-1β and IL-6. Some 
populations are known to be present in adipose tissue, but have unknown function in 
regulating metabolism due to few published findings or contradictory results. These 
include, but are not limited to, natural killer T cells (NKT), mast cells and γδ T cells.  
The prevailing model suggests that the cytokine environment of lean adipose 
tissue helps to promote M2-like macrophages and preserves insulin sensitivity. The 
inflammatory cytokine environment associated with obese adipose tissue initiates a cycle 
of chronic inflammation and leukocyte accumulation which promotes insulin resistance 
both locally and systemically. For the purposes of this introduction, I will provide more 
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detail on what’s known regarding T cell and macrophage population dynamics within 
adipose tissue. These are the best studied adipose tissue leukocyte populations and an 
extensive background literature exists regarding these cells in the context of obesity.  
 
Table 3 – Relative leukocyte population changes in murine epididymal adipose tissue with 
obesity. Data derived from our own data, Mraz and Haluzik 2014, and Sun et al.2012  (97; 103). 
Leukocyte Population Relative Change (% of SVF) 
Macrophage Increased 
Dendritic Cell Unknown/Possibly Increased 
CD4
+
 T cell (non-Treg) Increased 
CD4
+ 
Regulatory T cell Reduced 
CD8
+
 T cell Increased 
B cell Increased 
Eosinophil Reduced 
Natural Killer T cell Reduced 
Natural Killer cell Increased 





Figure 1-2 – Cartoon depiction of leukocyte population changes that occur with obesity and 
the resulting inflammatory signaling cascade that promotes insulin resistance. The cytokine 
environment and leukocyte populations found in lean adipose tissue are thought to promote the 
continued maintenance of low inflammation, insulin tolerance, and proper adipose tissue 
function. Obesity induces dramatic changes in the cytokine expression profile of adipose tissue 
which perpetuates a cycle of inflammatory leukocyte activation and recruitment. These 
inflammatory changes are thought to be central to the development of adipose dysfunction, 
insulin resistance, and, ultimately, cardiometabolic diseases. ILC2 = Innate lymphoid group 2 
cells; CTL = Cytotoxic T lymphocyte; Treg = Foxp3
+
 regulatory T lymphocyte. 
 
T Lymphocytes 





lymphocytes in adipose tissue. Obesity is also associated with qualitative shifts in the 
polarization state of adipose-resident T cell populations. Adipose tissue of lean mice has 
a higher frequency of naïve T cells and Foxp3
+ 
Tregs (110). With obesity there’s a 
reduction in the relative frequency of Tregs and naïve T cells in visceral adipose tissue. 
Instead, T cells from visceral adipose tissue of obese mice tend to polarize towards a type 
1 cytokine signature with increased production of IFNγ and granzyme B (111). We’ve 
observed T cell accumulation and activation in eWAT as early as 2-3 weeks after starting 
HFD with elevated IFNγ and IL-2 production observed after ex vivo stimulation (Figure 
1-3). IFNγ deficient mice have reduced adipose tissue macrophage (ATM) accumulation 
and reduced pro-inflammatory cytokine expression including TNFα and MCP-1 (111). 
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Depletion of T cells in WT DIO mice with a CD3-specific antibody increases adipose 
tissue Tregs and ameliorated insulin resistance for months despite continued HFD 
exposure (112). CD8-deficient mice also have reduced ATM accumulation, adipose 
tissue inflammation, and improved systemic insulin resistance (109).  
Interestingly, despite lacking all T and B cells, obese Rag1
–/–
 mice still develop 




still accumulate ATM. These data show that T cells are not necessary for obesity-
associated insulin resistance development. However, Rag1
–/–
 mice also lack cells thought 
to help regulate inflammation within adipose tissue including CD4
+
 Th2-polarized cells 




T cells into DIO 
Rag1
–/– 
mice increased Th2-polarized adipose tissue T cells and improves insulin 
resistance (112). Depletion of Tregs in Foxp3-DTR transgenic mice increased adipose 
tissue inflammation and increased serum insulin levels (110). Overall, the literature 
suggests that the balance of adipose-resident pro-inflammatory T cells (Th1, Th17, and 
CD8
+
 cytotoxic T cells) versus regulatory T cells (Th2 and Tregs) is critical for 
determining the development of obesity-associated inflammation and insulin resistance.   
There are several outstanding questions in the field regarding the mechanisms 
mediating T cell activation and polarization during obesity. The antigens responsible, 
which antigen presenting cells (APC) are involved, where T cell activation and expansion 




Figure 1-3 – Early progressive accumulation and activation of epididymal adipose tissue T 
cells in diet-induced obese C57BL/6J mice. (A-C) Obesity promotes the accumulation of CD3
+ 
T cells in eWAT which increases with more time spent on HFD. As early as 2 weeks on HFD (D 
and G) CD4+ T cells polarize towards expression of IFNγ and IL-2 after ex vivo stimulation with 
phorbol 12-myristate 13-acetate and ionomycin while (E and H) CD8+ T cells show no change in 
IFNγ but increased IL-2 expression. For A-H, cells were analyzed by flow cytometry after 
isolation from whole epididymal adipose tissue using collagenase digestion. 
 
Macrophages 
In 2003, two publications by Xu et al. and Weisberg et al. demonstrated that 
macrophages accumulated in obese adipose tissue but did not increase in other organs 
such as liver, lung or spleen (113; 114). More importantly, these two groups concluded 
the accumulated ATMs were primarily responsible for the elevated TNFα, iNOS and IL-
6 expression observed in obese adipose tissue. ATM accumulation in obese human 
subjects is primarily observed in the visceral omental fat depot but, to a lesser degree, 
ATMs also accumulate in the subcutaneous adipose tissue (115; 116). In mice, ATM 
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accumulation during obesity is also primarily observed in the visceral eWAT depot, but 
also occurs in subcutaneous depots.  
ATMs are also found in the adipose tissue of lean mice and humans. ATMs from 
adipose tissue of lean mice express a gene profile similar to M2 alternatively activated 
macrophages including Il10, Ym1, Arg1, and Mgl1. In 2007, it was found that obesity 
promotes the CCR2-dependent accumulation of a pro-inflammatory CD11c
+ 
ATM 
population which did not express these M2-like genes and, instead, produced 
inflammatory mediators including TNFα and iNOS (117). These recruited CD11c+ 
ATMs become the dominant ATM population and make up as much as 60-75% of all 
eWAT ATMs during obesity. More than 90% of macrophages in the adipose tissue of 
obese mice and humans localize to dead, or dying, adipocytes forming clusters which are 
now referred to as crown-like structures (CLS) (118). Lumeng et al. found that the CLS-
associated macrophages in obese eWAT expressed M1-like proinflammatory markers 
and were primarily derived from newly recruited macrophages (119). These publications 
provided evidence for a new way to identify and separate murine ATMs based on surface 
marker expression which correlated with functional polarization differences. Resident 







leukocytes. The recruited pro-inflammatory ATMs that 







(Figure 1-4).  
Recruited CD11c
+
 ATMs are believed to be critical for the development of 
metabolic dysfunction in obese mice. In support of this, depletion of ATMs during 
obesity with liposome-encapsulated clodronate improves insulin resistance and reduces 
hyperglycemia in DIO and leptin-deficient mice (120; 121). Ablation of CD11c
+
 cells, 
through use of CD11c-driven expression of diphtheria toxin receptor improved insulin 
sensitivity and reduced inflammatory markers within adipose tissue (122). Use of CCR2 
antagonists in DIO mice reduced ATM content, reduced adipose tissue inflammation and 
improved insulin resistance without lowering body weight or reducing hepatic steatosis 
(123). Overexpression of the CCR2 ligand, CCL2, specifically in adipose tissue increases 
macrophage accumulation, insulin resistance, and hepatic steatosis. Alternatively, CCL2-
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deficient DIO mice have reduced ATMs, reduced insulin resistance, and reduced hepatic 
steatosis (124). However, there’s no way to verify that the metabolic improvements 
observed in these studies were specifically due to the ATM population changes observed. 
There’s the potential for off-target effects on other adipose resident leukocyte populations 
(for example DCs) or even macrophage changes in other metabolic tissues which could 
be partly responsible for metabolic improvements. Methods of specifically targeting 
and/or differentiating ATMs are necessary to fully resolve the role that pro-inflammatory 




Figure 1-4 – Polarization of pro-inflammatory CD11c
+
 macrophages in adipose tissue 
during obesity. Obesity encourages the CCR2-dependent recruitment of blood monocytes which 
are activated towards an M1-like profile while in adipose tissue to produce pro-inflammatory 




leukocytes which were then separated by surface expression of markers like CD206 for anti-
inflammatory M2-like ATMs or CD11c for M1-like inflammatory ATMs.  
 
Scope of the Dissertation 
Excellent progress has been made in the last decade towards understanding the 
molecular and cellular drivers of inflammation during the onset of obesity. Unfortunately, 
much less is known about how inflammation and adipose-resident leukocytes are altered 
after weight loss in formerly obese subjects. Recent publications have begun to suggest 
certain obesity-associated features, such as adipose tissue inflammation, persist through 
weight loss despite improvements in systemic insulin resistance and glycemic control in 
both mice and humans (125; 126). Maintenance of inflammation after weight loss has 
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been largely evaluated by whole tissue gene expression and little is known regarding 
what changes occur in adipose-resident leukocyte populations or their activation profiles. 
We also don’t know how these persistent obesity-associated features may impact local 
and systemic metabolic health in formerly obese mice.  
My research has focused on trying to better understand the dynamics of adipose 
tissue leukocytes during weight loss and to identify potential residual metabolic 
abnormalities that persist in formerly obese mice. Presented below are specific 
backgrounds, motivations, and objectives for three major projects completed in pursuit of 
this research.   
 
Context for Chapter 2 – Definitive delineation of adipose tissue macrophages and 
adipose tissue dendritic cells in mouse and humans 
Historically, F4/80 has been used as a macrophage-specific marker in adipose 
tissue. However, it is well known that F4/80 is a poor marker for separating certain 
myeloid populations, such as DCs and eosinophils, in other tissues (127). Similarly, 
CD11c is often used as a classic marker for the identification of DCs, but CD11c is also 
upregulated on activated macrophages and ATMs during obesity. As a result, the 
separation of these two adipose tissue myeloid populations using historic markers has 
been difficult and imprecise. Upon starting this project, the exact discrimination of 
macrophages and dendritic cells in adipose tissue was poorly defined. Part of this was 
due to the need for better markers to define their respective functions in adipose tissue. 
Delineation of ATMs and ATDCs is important for understanding if they play synergistic, 
redundant, or even antagonistic functions in establishing and maintaining adipose tissue 
inflammation during obesity.  
Our objective was to test a new macrophage-specific marker (CD64) for 
discrimination of ATMs from adipose tissue DCs (ATDC). We show that F4/80 is 
expressed on other adipose-resident leukocyte populations, including eosinophils and 
DCs, in addition to labeling ATMs. Using this marker, we were able to distinguish 
CD11c
+
 ATMs and CD11c
+
 ATDCs and we verify our findings by showing distinct gene 
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expression profiles for these two populations. Through this work, we hope to improve our 
understanding of the relative functions of ATM versus ATDC during obesity and weight 
loss. Other markers, such as F4/80 or CD11b, can be used in conjunction with CD64 but 
we have found add little additional discriminatory value beyond what CD64 provides. 















Context for Chapter 3 – Features normally associated with obesity persist in visceral 
adipose tissue despite weight loss 
Weight loss is often seen as the optimal resolution of obesity and obesity-
associated comorbidities. However, some patients still retain a persistently elevated risk 
for cardiometabolic disease despite weight loss (125; 126; 128). Adipose tissue 
leukocytes are linked to obesity-associated insulin resistance and cardiometabolic disease 
development during obesity. However, few groups have attempted to investigate how 
adipose tissue leukocytes are altered during weight loss. Several recent studies have 
found that weight loss fails to resolve adipose tissue inflammation in mice and humans 
(125; 126; 129; 130), and suggest certain adipose tissue leukocyte populations remain 
activated despite weight loss. Persistent activation of adipose tissue leukocyte 
populations may provide a potential mechanism to explain elevated cardiometabolic 
disease risk after weight loss. 
Our objective was to define the effects of weight loss on inflammatory leukocyte 
activation and composition within adipose tissue to understand the mechanisms by which 
metabolic inflammation persists. We identified long-term alterations in the composition 
of adipose tissue leukocytes including retention of proliferating CD11c
+
 ATMs and a 
persistent activation state of ATMs despite weight loss. We also identified maintenance 
of obesity-associated derangements in eWAT structure and function after weight loss 
including fibrosis, crown-like structures, and altered adipogenic protein expression. The 
results from this project show that obesity imparts long-term, potentially permanent, 
alterations in eWAT that fail to resolve with weight loss (Figure 1-5). Understanding 
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which characteristics of obesity remain despite weight loss helps inform our 
understanding of the relationship between adipose tissue inflammation and metabolic 
function. 
 
Figure 1-5 – Features normally associated with obesity persist in adipose tissue despite 
weight loss. After weight loss, adipose tissue of formerly obese mice fails to return to a lean-like 
state and, instead, maintains or develops several features normally only associated with 
chronically obese adipose tissue. These features include crown-like structures, increased 
leukocyte accumulation, inflammatory activation of resident leukocytes, and impaired adipogenic 
protein expression profile. PPARg = Peroxisome proliferator-activated receptor gamma; IRS-1 = 
Insulin receptor substrate 1; AKT = Protein kinase B (These are proteins important for adipocyte 
function and development). 
 
Context for Chapter 4 – Formerly obese mice develop metabolic abnormalities faster 
than formerly lean mice after HFD re-challenge 
Unfortunately, weight regain is a common occurrence in formerly obese subjects. 
An open question within the field is whether weight regain adversely alters metabolic 
health. Based on the findings of Chapter 3, we hypothesized there would be unique 
metabolic abnormalities in formerly obese mice that only manifest during weight regain 
(Figure 1-6). We sought to identify these potential metabolic abnormalities by re-
exposing formerly obese mice with an additional HFD challenge. In chapter 4, I will 
present evidence suggesting that weight regain causes metabolic abnormalities to develop 
at a hastened rate in formerly obese mice due to unresolved effects that persist through 
weight loss. These findings could help identify unique health consequences of weight 





Figure 1-6 – Cartoon model depicting predicted metabolic perturbations after HFD re-
challenge. Weight loss fails to fully resolve obesity-associated features within eWAT including 
the maintenance of pro-inflammatory ATMs. We hypothesize that these ATMs directly influence 
the adipogenic responsiveness of eWAT preadipocytes during HFD re-challenge of formerly 
obese mice. As a result, the eWAT tissue fails to respond due to a shortage of functional mature 
adipocytes. This encourages increased ectopic lipid deposition in organs such as liver and 
increases plasma insulin levels. 
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Chapter 2 – Adipose Tissue Dendritic Cells are Independent Contributors to 
Obesity-Induced Inflammation and Insulin Resistance 
 
Portions of this chapter have been published: 
Kae Won Cho*, Brian F. Zamarron*, Lindsey A. Muir, Kanakadurga Singer, Cara E. 
Porsche, Jennifer B. DelProposto, Lynn Geletka, Kevin A. Meyer , Robert W. O’Rourke, 
and Carey N. Lumeng. Adipose Tissue Dendritic Cells are Independent Contributors to 
Obesity-Induced Inflammation and Insulin Resistance. Journal of Immunology. 2016 
Nov 1;197(9):3650-3661.  PMID: 27683748. *Both authors contributed equally 
Abstract 
Dynamic changes of adipose tissue leukocytes, including adipose tissue 
macrophages (ATM) and adipose tissue dendritic cells (ATDC), contribute to obesity-
induced inflammation and metabolic disease. However, inability to clearly discriminate 
between ATDCs and ATMs in adipose tissue has limited progress in the field of 
immunometabolism. In this study, we utilize CD64 to distinguish ATMs from ATDCs 
and investigated the temporal and functional changes in these myeloid populations during 


























 ATDCs expressed MHCII and co-stimulatory 
receptors and had similar capacity to stimulate CD4
+
 T cell proliferation as ATMs. 
ATDCs were predominantly CD11b
+
 conventional DCs and made up the bulk of CD11c
+
 
cells in adipose tissue with moderate high-fat diet exposure. Mixed chimeric experiments 
with Ccr2
–/–
 mice demonstrated that high-fat diet induced ATM accumulation from blood 
monocytes was dependent on CCR2, while ATDC accumulation was less CCR2-
dependent. ATDC accumulation during obesity was attenuated in Ccr7
–/–
 mice and was 











ATDCs were also identified in human 
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obese adipose tissue and ATDCs were increased in subcutaneous adipose tissue 
compared to omental. These results support a revised strategy for unambiguous 
delineation of ATMs versus ATDCs, and suggest that ATDCs are independent 
contributors to adipose tissue inflammation during obesity.  
 
Introduction 
Obesity-induced inflammation is believed to be a potent contributing factor to the 
development of type 2 diabetes and metabolic dysfunction. Metabolic inflammation is 
driven largely by the induction of inflammation in adipose tissue of obese subjects and is 
regulated by a network of adipose tissue leukocytes (98; 131). The inflammatory 
components in adipose tissue include both innate and adaptive immune cells that undergo 
both qualitative and quantitative changes with obesity. Myeloid cells were among the 
first leukocytes identified as being deranged in adipose tissue and in the circulation of 
obese subjects (132). Obese children, as young as three years old, have increased 
circulating neutrophils indicating an early influence of obesity on myeloid cell regulation 
(133). Associations between classical monocytes (Ly6c
hi





humans), adipose tissue macrophage content, and insulin resistance suggest a mechanistic 
contribution of myeloid cells to the development of metabolic disease with obesity (134; 
135). Furthermore, obesity-induced activation of neutrophils and macrophages in adipose 
tissue are required for insulin resistance in obese mice and correlate with metabolic 
disease in humans (117; 136).  
Adipose tissue macrophages (ATM) are a dominant innate immune cell in adipose 
tissue and can comprise up to 40% of the non-adipocyte stromal vascular fraction (SVF) 











 ATM population accumulates 
(119; 139). The importance of CD11c
+
 ATMs has been emphasized in numerous studies 
in both mice and humans (135; 139; 140). Obesity increases blood monocyte recruitment 
into adipose tissue and induces pro-inflammatory activation and upregulation of CD11c 
(141). Ablation of CD11c
+
 cells attenuates adipose tissue inflammation and improves 
glucose tolerance without changes in body weight (122; 142). CD11c
+
 ATMs have been 
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described as having a metabolically active phenotype with lysosomal activation and 
characteristics of classically activated M1 macrophages (137; 138). In addition to 
classical innate immune cytokine production, ATMs express high levels of MHC class II 
and are active antigen presenting cells that shape the expansion of conventional Th1 
CD4
+
 T cells, induction of effector/memory T cells, and the attenuation of regulatory T 
cells (Tregs) (142-144).   
The accumulation of CD11c
+
 cells in adipose tissue suggests the possibility that 
adipose tissue dendritic cells (ATDC) may also play a role in obesity-associated 
inflammation. Ex vivo, ATDCs can induce a Th17 profile in T cells that may explain the 
associations between Th17 cytokines and insulin resistance (145). ATDCs can contribute 
to the regulation of adipose tissue expansion by controlling adipose tissue T cell clonal 
expansion (146). GM-CSF-dependent DCs have also been shown to contribute to adipose 
tissue expansion in lean animals (147). However, since CD11b and F4/80 expression 
overlaps between macrophages and DCs, it has been difficult to clarify the relative 
contribution of ATDCs towards adipose tissue inflammation. In mouse obesity models, 















 leukocytes depending on the study (145-150). Based on these 
definitions, conventional (cATDC) and plasmacytoid (pATDC; B220
+
) ATDCs have 





 ATM has not been clarified.   
Almost all studies of murine ATMs have utilized F4/80 as the primary marker 
despite its known expression on non-macrophage leukocytes such as DCs and 
eosinophils. The Immunologic Genome Consortium identified markers including CD64 
and MerTK that improve the specificity of tissue macrophage phenotyping in several 
tissues (151). The use of CD64 has been useful in untangling macrophage and DC 
identity and diversity in the gut (152; 153). In this study, we used CD64 to revisit the 
F4/80 ATM phenotyping strategy in hopes of improving our understanding of the 
dynamics and functions of ATM and ATDC during obesity. We support the use of CD64 




 labeling defines a pure 
population of bona-fide myeloid ATDC present in lean and obese states in both mice and 
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humans. We distinguish CD11c
+
 ATMs and CD11c
+
 ATDCs induced by obesity with 
distinct gene expression profiles and lipid storage capacity. Using competitive 
reconstitution experiments, CD11c
+
 ATM accumulation was found to be CCR2-
dependent while ATDC recruitment was only partially CCR2-dependent. With moderate 
high fat diet feeding, ATDC are the dominant CD11c
+
 cell population induced in adipose 
tissue. Studies using Ccr7
-/-
 mice reveal decreased ATDC content and mice were 
protected from insulin resistance development. This work increases the resolution by 
which adipose tissue myeloid cells can be identified and suggests that ATDCs are an 
independent contributor to obesity-induced adipose tissue inflammation. 
 
Materials and Methods 
Animal studies 
CD45.1 and CD45.2 C57BL/6J mice, CC chemokine receptor (CCR) 7
–/–
 
(B6.129P2(C)-CCR7tm1Rfor/J), and OT-II (B6.Cg-Tg (TcraTcrb)425Cbn/J) mice were 




 mice were kindly provided by 
Dr. Beth Moore and Dr. John Osterholzer at the University of Michigan, respectively. 
Male mice were ad libitum fed a control normal diet (ND; 4.09 kcal/g; 29.8% protein, 
13.4% fat and 56.7% carbohydrate; PicoLab 5L0D, LabDiet) or fed a high-fat diet (HFD; 
5.24 kcal/g; 20% protein, 60% fat and 20% carbohydrate; Research Diets) ad libitum 
beginning at 6 weeks of age. All animal experiments were approved by the University 
Committee on Use and Care of Animals at the University of Michigan and conducted in 
compliance with the Institute of Laboratory Animal Research Guide for the Care and Use 
of Laboratory Animals.  
 
Bone marrow transplantation   
Competitive bone marrow transplants were performed as described (154). Briefly, 









) and mixed in a 1:1 ratio. Six week old CD45.1 mice were lethally irradiated 
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(900 Rad) and intravenously injected six hours after irradiation with 10 × 10
6
 cells of the 
mixed bone marrow donor cells re-suspended in 150 μl of PBS. Bone marrow 





 ratios at 6 weeks after transplantation, and recipient animals were fed 
either a ND or HFD for 15 weeks.   
 
Human adipose tissue  
Human omental and subcutaneous adipose tissues were collected intraoperatively 
from patients undergoing bariatric surgery at the University of Michigan and the Ann 
Arbor VA Hospital. All human use protocols were approved by the University of 
Michigan and Ann Arbor VA Hospital Institutional Review Boards.  
 
Immunofluorescence microscopy 
Immunofluorescence staining was performed as described (155) using the 
following antibodies: anti-CD64 (X54-5/7.1), anti-F480 (A3-1), anti-Mgl1 (MP23), anti-
CD11c (N418), anti-Mac2 (M3/38), and anti-Caveolin (2297). Images were collected 
using an Olympus Fluoview 100 laser scanning confocal microscope.  
 
SVF isolation and flow cytometry analysis 
Stromal vascular fraction cells (SVF) were isolated as described previously (156). 
Cells were incubated in Fc Block for 10 min on ice and stained with indicated antibodies 
for 30 min at 4°C. Antibodies used for flow cytometry in this study are provided in Table 
4. Live/dead fixable violet staining kits (Life Technology) and BODIPY (Life 
Technology) were used according to the manufacturers’ instruction. Cells were analyzed 
on a FACSCanto II Flow Cytometer (BD Biosciences) using FlowJo 10.6 software 
(Treestar). For fluorescence-activated cell sorting (FACS), SVF were suspended in 
RPMI/2%HI-FBS and purified by FACSAria III (BD Biosceinces). Fluorescence minus 
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one controls were used to confirm SiglecF, Ly6G, and CD11c expression in SVF 
analyses in mice and humans in at least three independent experiments.   
 
Microarray and real-time RT-PCR 
Male C57BL/6 mice fed normal diet or HFD for 20 weeks were used for gene 




















) and sorted using a BD FACSAria III cell sorter. Microarray 
analyses were carried out as previously described (49). RNA was extracted using QIAzol 
(Qiagen) and amplified and hybridized on the Affymetrix Mouse Gene 2.1 ST array. 
RNA quality was assessed on Agilent Bioanalyzer Picochip. After quality control 
assessments probe sets with unadjusted p-value of 0.05 or less were identified. 
Differences in gene expression were identified and analysis was performed through the 
University of Michigan Microarray Core using affy, limman, and affy PLM packages of 
bioconductor implemented in the R statistical environment.  
 
For real-time PCR, RNA from tissues and cells was prepared using RNeasy Midi 
Kits (QIAGEN), and cDNA was generated using high-capacity cDNA reverse 
transcription kits (Applied Biosystems). Real-time RT-PCR analyses were done in 
duplicate on the ABI PRISM 7900 Sequence Detector TaqMan System with the SYBR 
Green PCR kit as instructed by the manufacturer (Applied Biosystems). Primer sequences 
used for this study are shown in Table 5. Arbp or 18S was used as a housekeeping 





CFSE dilution assay 
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Antigen-specific T cell activation assay was performed as previously described 
(144). Briefly, FACS-sorted cells were grown in 90-well U bottom plates, then pulsed 
with 100 µg/ml whole OVA (ThermoScientific). CD4
+
 T cells were isolated from the 
spleen of OT-II mice using CD4+ T cell negative selection kites (Miltenyi Biotec). CD4
+
 
T cells were labeled with 2 µmol/L carboxy fluorescein succinimidyl ester (CFSE) and 
added to antigen-pulsed cells at a 1:1 ratio. After 5 days, T cells were stained for flow 




 lymphocytes.  
 
Metabolic evaluation 
Body weights were measured weekly. Blood glucose and plasma insulin were 
measured by glucometer and an insulin ELISA kit (Crystal Chem), respectively.  
 
Statistical Analysis 
Data are expressed as means ± SEM. Statistical differences were assessed using a 
2-tailed t test or analysis of variance (with Tukey’s post-test analysis), using GraphPad 




Figure 2-1 – CD64 is a specific ATM marker in lean and obese mice. Analysis of SVF from 
eWAT of C57BL/6 mice fed with ND or HFD for 20 weeks. (A) Flow cytometry analysis of 
eosinophils (siglec-F
+




 cells after gating CD45
+
 stromal 




 SVF cells (red) 
and neutrophils (blue) from obese mice. (C) Analysis of Siglec-F expression in CD64 stratified 
SVF cells. (D) Comparison of CD64 and F4/80 staining in SVF from ND and HFD fed mice. (E) 











 (bottom) SVF cells from lean mice. (F) Immunofluorescence analysis of CD64
+
 





 cells. Data are representative of at least three independent 
experiments with three mice per group. 
 
Results 
CD64 distinguishes ATMs from eosinophils, neutrophils, and ATDCs in lean and obese 
mice 






 cells in the 
SVF despite the potential for non-macrophage F4/80
+
 cell contamination. Co-staining 
with markers for eosinophils (Siglec-F) and neutrophils (Ly6G) demonstrated that these 






fraction in both lean and obese mice 
(Figure 2-1A-B). We examined the utility of CD64 as a more specific marker of ATM in 
lean and obese (HFD fed for 10-12 weeks) mice. Adipose tissue eosinophils were CD64
–
 
in both lean and obese mice (Figure 2-1C) with CD64
+
 macrophages showing 
intermediate SiglecF expression. Using CD64 and CD11c, lean mice demonstrated 













cells (Figure 2-1D).  In obese mice, there was 


















 cells expressed CD11b and F4/80, 













 cells in both lean 
and obese adipose tissue were CD64
–
, further supporting the presence of non-macrophage 
cells within the F4/80
+





 ATM in lean mice have high expression of markers for 
alternatively activated macrophages such as CD206 and CD301/Mgl1 (157). In lean mice 
82% of the of the CD64
+
 population were also CD206
+







cells identified (Figure 2-1E). The ability of CD64 to identify ATMs was further 
confirmed with immunofluorecence microscopy. There was co-localization of F4/80 and 
CD64 staining in lean mice, however F4/80
+
 cells were also identified that did not stain 
for CD64. Co-localization between Mgl1 and CD64 staining was prominent in lean 
adipose tissue (Figure 2-1F). In obese mice, where CD11c
+
 cells accumulate in adipose 
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tissue, co-localization between CD11c and CD64 was observed. However, distinct 
populations of CD11c
+
 cells were identified that did not stain positive for CD64 in obese 
adipose tissue. Mac2 and CD64 staining showed significant overlap, especially in crown-
like structures (CLS) where dense myeloid cell accumulation is known to occur. 
 
Gene expression profiling supports distinguishing ATM and ATDC based on CD64  








































leukocytes from lean mice were not included in the analysis. When compared against the 
ImmGen core set of macrophage specific genes (151), CD64
+
 cells were significantly 
enriched for macrophage-related genes in both lean and obese mice (Figure 2-2A). In 
contrast, expression of the core DC-related genes was highly enriched in CD64
–
 cells in 





 cells from adipose tissue confirmed these differences (Figure 2-2C). 
Core macrophage-related genes such as Mertk and Camk1 were highly expressed in 
CD64
+ 










Figure 2-2 – Gene expression profiling of ATMs and ATDCs. Microarray analysis heat map of 
ImmGen (A) macrophage core signature genes and (B) DC core signature genes from adipose 






















. (C) Quantitative PCR analysis of macrophage-specific genes (upper panel) and 




 double negative (DN), CD64
+
 (ATM), and 
CD11c
+
CD64- (ATDC) cells from eWAT of obese mice. (D) Gene Set Enrichment Analysis 
pathways enriched in ATDCs and CD11c
+
 ATMs. Heat maps shown for differentially expressed 
genes for (E) graft-versus-host disease and (F) complement and coagulation cascade. (G) 
Intracellular cytokine staining for ATMs and ATDCs from ND and HFD fed mice eWAT. (H) 
Flow cytometry analysis of intracellular lipid content in CD64
+





ATDCs from obese mice. Data are from two independent experiments with three mice per group. 
*p < 0.05. 
 
Gene Set Enrichment Analysis was used to identify uniquely enriched networks in 
ATDCs and CD11c
+
 ATMs in obese mice (Figure 2-2D). The top category for ATDCs 
was enrichment for genes involved in Graft vs Host Disease and interactions between 
antigen presenting cells and lymphoid cells. Examining this set showed that ATDCs are 
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enriched for the expression of cytokine genes including Il2, Il1a, Ifng, and Il1b, but not 
for Il6 and Tnfa (Figure 2-2E-F). We confirmed this by intracellular cytokine staining 




 ATMs compared to ATDCs in lean 
and obese mice (Figure 2-2G). For CD11c
+
 ATMs, Complement and Coagulation 
Cascade genes had the highest enrichment score along with genes involved in Glycan 
Biosynthesis and Lysosomes. A lipid-laden phenotype with activated lysosomes is 
associated with obesity and seen in obese rodent and human ATMs (115; 158). When 
ATMs and ATDCs from HFD fed mice were examined for lipid accumulation by 
BODIPY staining, ATMs had significantly higher BODIPY staining compared to ATDCs 
(Figure 2-2H). 
 
ATDC are predominantly CD11b
+
 conventional DCs  






 ATDC was examined to 
further evaluate the phenotypes of ATDCs (Figure 2-3A). Both ATMs and ATDCs from 
lean mice express MHCII, CD40, CD80, and CD86. All of these antigen presenting cell 
(APC) markers were expressed at higher levels in ATMs compared to ATDCs, which 
suggests an immature phenotype of ATDCs in lean mice. With obesity, MHCII 
expression on ATDCs was significantly increased (Figure 2-3B). We have previously 
shown that ATMs are potent functional APCs. In vitro T cell stimulation assays were 
performed to compare ATM and ATDC APC function (Figure 2-3C). CFSE labeled 
CD4
+
 T cells from OT-II mice were incubated with ATMs and ATDCs after loading with 
OVA (100 µg/ml). Both ATMs and ATDCs were able to stimulate T cell proliferation to 




Figure 2-3 – Myeloid DCs predominate in adipose tissue. (A) Flow cytometry analysis of 
MHCII and costimulatory molecules in CD64
+




 ATDC (red) from 
eWAT. (B) MHCII expression in ATDC in ND and HFD mice. (C) OTII-CD4
+
 T cell 
proliferation after incubation with OVA-pulsed CD64
+





(right).  One representative experiment from three independent replicates is shown. (D) ATDC 
subsets based on CD103, CD11b, CD4, CD8α, B220
 
and MHCII. (E) Quantitation of ATDC 
subsets in eWAT from ND- and HFD-fed mice. (F) Quantitation of ATM and ATDC in lean WT 
and Csf2
–/–
 mice. *p < 0.05; ***p < 0.001. 
 
Additional markers were used to identify ATDC subpopulations (Figure 2-3D). 
The majority of ATDCs in lean mice were CD11b
+









 ATDCs were also identified in lean mice suggesting that the 
majority of ATDCs are of the conventional CD11b
+
 type. In obese mice, CD11b
+
 
myeloid cDCs remained the dominant ATDC type and the quantity of CD11b
+ 
ATDCs, 
normalized to adipose tissue weight, was increased by two-fold compared to lean mice 
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 ATDC with 
HFD as well as a significant increase in ATDC that were negative for CD103, CD8 or 
CD11b. Consistent with the prominence of myeloid-derived CD11b
+
 cATDCs, ATDC 
content was decreased in Csf2
–/–
 mice (Figure 2-3F).  
 
Figure 2-4 – Time course of ATM and ATDC accumulation in adipose tissue with HFD-
induced obesity. C57BL/6 male mice were fed an HFD for various time periods (0, 8, and 16 




  ATMs, and ATDCs by flow 
cytometry normalized for adipose tissue mass. (B) Quantitation of ATMs and ATDCs in iWAT at 
16 wk of HFD. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
ATDC are a dominant CD11c
+
 population with moderate high fat diet exposure 





) and ATDCs in gonadal/epididymal adipose tissue (eWAT) (Figure 
2-4A). Mice were examined after 8 and 16 weeks of HFD feeding. 16 weeks of HFD 
induced a significant increase in body weight associated with eWAT hypertrophy and the 
development of fasting hyperglycemia (Data not shown). In lean mice, CD11c
–
 ATMs 
were the dominant myeloid cell population as a percentage of all CD45
+
 leukocytes. The 
majority of CD11c
+
 cells in lean mice were ATDCs and not ATMs. With eight weeks of 
HFD, both CD11c
+
 ATMs and CD11c
+
 ATDCs increased in number. At this time point, 
ATDCs were still the larger CD11c
+
 cell population in adipose tissue. 16 weeks of HFD 
exposure led to a substantial increase in CD11c
+
 ATMs and the maintenance of a 
prominent population of ATDCs. Inguinal adipose tissue (iWAT) ATM content was not 
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significantly increased with HFD feeding (Figure 2-4B). However, there was a significant 
induction of ATDCs in iWAT similar to what was seen in eWAT.   
 
Figure 2-5 – CCR2 is required for obesity-induced CD11c
+
 ATM and ATDC migration into 




 ATMs, and ATDCs in eWAT from 
WT and Ccr2
–/–




 ATDC subsets in eWAT from 
WT and Ccr2
–/–
 mice. (C) ATM and ATDC content in WT and Ccr2
–/–
 mice after 2 wk of ND or 
HFD feeding. (D) Diagram of mixed chimera experiment design. Ccr2
–/–
 (CD45.2) and WT 
(CD45.1) bone marrow mixed in a 1:1 ratio before injection in irradiated recipients. Chimerism 
analysis of blood leukocytes is shown. (E) Frequency and ratio of CD45.1 (WT) and CD45.2 
(Ccr2
–/–
) in blood monocytes from lean and obese (15-wk HFD) chimeric mice. (F) Frequency 




 ATMs, and ATDCs in eWAT. *p < 0.05, 




Differential recruitment dependence of CD11c
+
 ATMs and ATDCs on CCR2 during diet-
induced obesity 
Monocyte recruitment is a primary mechanism by which CD11c
+
 ATMs 
accumulate in adipose tissue during obesity (157; 159). Since our results suggest that the 






 ATM is contaminated with ATDCs and other 
leukocytes, we revisited ATM and ATDC accumulation in Ccr2
–/–
 mice using CD64. 
Ccr2
–/–
 mice had significantly reduced ATM and ATDC compared to WT (Figure 2-5A). 
Specifically, CD11b
+ 
ATDC were decreased in Ccr2
–/– 
mice, but there were no 
differences in CD11b
–
 ATDC (Figure 2-5B). With 2 weeks of HFD, we observed an 
increase in ATDC in WT, but not in Ccr2
–/– 
mice indicating that CCR2 is important for 
ATDC accumulation with short term HFD exposure (Figure 2-5C).  
Since Ccr2
–/–
 mice have fewer circulating monocytes (159), it is difficult to 
discern whether ATM and ATDC accumulation in adipose tissue relies on Ccr2 
dependent signals for trafficking or is dependent on the size of the blood monocyte pool. 
To evaluate this, we used a mixed chimera model where lethally irradiated recipients 
were reconstituted with a 1:1 mixture of bone marrow cells from WT (CD45.1) and 
Ccr2
–/–
 (CD45.2) donor mice (Figure 2-5D). After reconstitution, the chimeras were fed 
ND or HFD for 16 weeks. Blood chimerism analysis was performed to evaluate the ratio 
of WT:Ccr2
–/– 
cells (CD45.1/CD45.2) relative to the BM input ratio of 1. Analysis of 
total peripheral blood leukocytes demonstrated a slight bias towards reconstitution with 
cells from Ccr2
–/– 
donors with the ratio of WT:Ccr2
–/– 
cells (CD45.1/CD45.2) less than 1 
in both ND and HFD conditions. However, analysis of circulating CD115
+
 monocytes 
demonstrated a significant increase in monocytes derived from WT compared to Ccr2
–/–
 
mice with a WT:Ccr2
–/– 
ratio of 11.3 ± 1.6 (Figure 2-5E). Circulating WT derived cells 
dominated over Ccr2
–/– 




 blood monocyte subsets. This is 
consistent with the requirement of CCR2 to regulate monocyte exit from the bone 




EWAT ATMs were also examined in the chimeras (Figure 2-5F). As expected, 
CD64
+
 ATMs from ND fed mice were primarily CD11c
–
 while HFD induced CD11c
+
 
ATM accumulation. In lean mice, the WT:Ccr2
–/– 





ATMs was elevated (12.2 ± 2.2 and 11.9 ± 2.2, respectively) and was similar to what was 
observed in blood monocytes. This suggests that in a competitive reconstitution model 
both ATM subsets in lean mice may be dependent on circulating monocyte for 
reconstitution. In contrast, the WT:Ccr2
–/– 
ratio of ATDCs in lean mice was significantly 
lower (1.8 ± 0.16)  than what was observed in either ATMs or circulating monocytes. In 




 ATMs was markedly increased (74.7 ± 
11.7). This demonstrates that in the obese environment WT monocytes had a significant 
competitive advantage in trafficking to adipose tissue from the circulation compared to 
Ccr2
–/– 





ATMs suggesting that any accumulation of CD11c
–
 ATMs during obesity is CCR2 
independent. While the WT:Ccr2
–/–
 ratio of ATDCs was lower than that of blood 
monocytes in lean mice, there was a statistically significant increase in the WT:Ccr2
–/– 
ratio in ATDCs (3.0 ± 0.4) in obese mice suggesting some ATDCs are dependent on 
CCR2 for trafficking to adipose tissue with obesity. However, the increased accumulation 
of ATDCs during obesity was less dependent on CCR2 than CD11c
+
 ATMs (~1.6 fold 
increase for ATDCs versus ~6.3 fold increase for CD11c
+
 ATMs).  Overall this suggests 
that in chronic obesity, CCR2 signaling plays a critical role in regulating monocyte 
trafficking into obese adipose tissue to generate CD11c
+
 ATMs and, to a lesser degree, 
ATDCs. 
 
CCR7 is required for HFD-induced ATDC accumulation and insulin resistance.  
The microarray analysis identified Ccr7 as differentially expressed in ATDCs 
compared to ATMs. To evaluate whether CCR7 plays a role in the recruitment or 
maintenance of ATDCs in adipose tissue, age-matched male WT and Ccr7
–/–
 mice were 
fed ND or HFD ad libitum for 8 weeks. This feeding duration was chosen based on our 
observation that 8 weeks led to increased ATDCs but minimal accumulation of CD11c
+
 




 ATMs did not differ 
41 
 
between genotypes. However, Ccr7
–/–
 mice had significantly fewer ATDCs compared to 
WT mice primarily due to a decrease in CD11b
+
 ATDCs (Figure 2-6A-B). Eight-week 
HFD challenge induced CD11c
+
 ATM and ATDC accumulation in both genotypes, but 
HFD-induced ATDC accumulation was significantly impaired in Ccr7
–/–
 mice when 
normalized to adipose tissue weight (Figure 2-6C). CD11b
+
 ATDCs in Ccr7
–/–
 adipose 
tissue were ~50% lower than WT adipose tissue. Meanwhile, the quantity of CD11b
– 
ATDCs was similar between genotypes (Figure 2-6D). After 8-weeks of HFD, Ccr7
–/–
 





 monocytes compared to WT (Figure 2-6E). Importantly, there was no difference 
in the accumulation of splenic macrophages and DCs between genotypes (Figure 2-6F). 
These data suggest that HFD induces ATDC accumulation via CCR7-dependent 
increases in CD11b
+
 ATDCs.  
 
Figure 2-6 – CCR7 is required for ATDC accumulation during diet-induced obesity. (A) 
Quantitation of ATMs and ATDCs in eWAT from chow-fed WT and Ccr7
–/–


















 ATMs, and ATDCs in eWAT from 
WT and Ccr7
–/–




 ATDC subsets 
in eWAT from WT and Ccr7
–/–





monocytes from WT and Ccr7
–/–
 mice. (F) Frequency of macrophages and DCs in spleen from 
WT and Ccr7
–/–
. *p < 0.05, **p < 0.01. 
 
 
Figure 2-7 – CCR7-deficient mice are protected from HFD-induced insulin resistance and 
adipose tissue inflammation. (A) Body weights of WT and Ccr7
–/–
 mice during 8-wk HFD 
feeding. (B) Organ weights at the end of HFD exposure. (C) Fasting blood glucose and plasma 
insulin levels. (D) HOMA-IR in WT and Ccr7
–/–
 mice fed HFD for 8 wk. (E) 
Immunofluorescence imaging of Mac2
+
 ATM (red) and caveolin
+
 adipocytes (green) in eWAT. 
Scale bar, 100 mm. (F) Expression of select immune-related genes in eWAT from HFD-fed WT 
and Ccr7
–/–
 mice. *p < 0.05, **p < 0.01, #p = 0.06.  
 
We next examined the impact of Ccr7 deficiency on HFD-induced insulin 
resistance and adipose tissue inflammation. Total body weight between the genotypes 
was not significantly different on HFD (Figure 2-7A). Ccr7
–/–
 mice had lower total 
eWAT weights (Figure 2-7B). Inguinal adipose tissue (iWAT) and liver weights were 
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similar between genotypes. Compared to WT mice, Ccr7
–/–
 mice had lower fasting 
glucose levels and lower fasting insulin levels resulting in improved insulin sensitivity in 
Ccr7
–/–
 mice based on the calculation of HOMA-IR (Figure 2-7C-D). Whole mount 
imaging of eWAT showed a significant accumulation of Mac2
+
 cells in CLSs of WT 
eWAT, whereas CLSs were largely absent in Ccr7
–/–
 eWAT (Figure 2-7E). Consistent 
with the flow cytometry data, gene expression of Itgax and Flt3 were decreased in Ccr7
–/– 
eWAT. In addition, Ccl2 and IL-6 expression were decreased and Foxp3 expression was 
increased in Ccr7
–/–
 eWAT (Figure 2-7F). Obese Ccr7
–/–





 cells suggesting that metabolic protection in these mice is not due to 
fewer T cells (data not shown). Overall, these data suggest that CCR7-dependent signals 
contribute to insulin resistance and adipose tissue inflammation by regulating ATDC 








 ATDCs are enriched in subcutaneous adipose tissue from obese 
humans. (A) SVF was isolated from human omental (OM) and subcutaneous adipose tissue, and 
analyzed by flow cytometry. Analysis of CD64-expressing cells and overlap with CD14 in OM. 













 ATMs in OM. (C) Contour 













 ATMs in paired OM and subcutaneous adipose 




 ATDC are enriched in subcutaneous adipose tissue from obese humans 
A range of markers have been used to quantify human ATMs in published studies 
and many rely on CD14 as an ATM marker despite the demonstration of CD14
+
 DCs 
(160). We therefore wanted to evaluate the utility of CD64 in delineating ATMs from 
ATDCs in human samples. Multi-color flow cytometry was performed on SVF cells from 
subcutaneous and omental/visceral adipose tissue (OM) from obese subjects undergoing 
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 cells was 



















 stained uniformly positive for CD14
+
. 
However, a minor population of CD14
+


























 myeloid leukocyte populations 






 cells had the highest CD1c expression and moderate HLA-DR expression 









 cells, consistent with mouse studies suggesting this is the phenotype of 
resident ATMs in lean adipose tissue. CD64
+
 cells were CD16
–





 cells were a mix of monocytes and neutrophils based on side scatter 





as we observed in mice. 
We next examined the proportion of ATDC (CD64
–
) and ATM (CD64
+
) subsets 









 ATMs were lower in subcutaneous adipose. The frequency of ATDCs was 
higher in subcutaneous compared to omental adipose tissue. Collectively these results 
indicate that ATDCs are enriched in the subcutaneous adipose tissue of obese humans. 
 
Discussion 
There is considerable interest in the contribution of myeloid cells to obesity-
induced inflammation and metabolic disease pathogenesis. Unfortunately, the adipose 
tissue myeloid cellular network is complex and we lack good markers for properly 
delineating the relatively contributions of the adipose-resident leukocytes. The primary 
goal of this study was to identify a better marker for identifying ATMs from other 
leukocyte populations including ATDCs. By using CD64 as a macrophage-specific 














 cell subset was contaminated with ATDCs. ATDCs comprise a 
significant portion of the total myeloid network in adipose tissue and this contamination 
may substantially confound results obtained when using F4/80 as an ATM-specific 
marker. A secondary goal was to use this newly identified marker to examine how ATM 
and ATDC accumulation is regulated during obesity. ATDC accumulation appears to be 
regulated by different chemotactic cues compared to ATMs. ATDCs were found to be 
CCR7-dependent with Ccr7
–/–
 mice having fewer ATDC and being protected from 
obesity-induced inflammation and insulin resistance. On the other hand, ATM 
accumulation with obesity was confirmed to be primarily CCR2-depdendent. 




 by our group and 
others (117; 158; 161). Our experiments suggest that some studies may need to be re-







population may actually be accounted for by changes in ATDCs. In addition, our 
experiments suggest that the use of CD11c as a single marker to define ATDC, which has 
been utilized by some groups, is inadequate given the clear identification of CD11c
+
 
ATMs (149). Our studies agree with the results of the ImmGen Consortium supporting 
the specificity of CD64 as a marker of tissue macrophages (150; 151). In addition, we 
have extended their results to the study of obese mouse models and obese human adipose 
tissue and support the specificity of CD64 as a marker of ATMs in both contexts.  
 Our observation that ATDCs increase with early obesity and are a dominant 
CD11c
+ 
population in adipose tissue with moderate HFD may be important for the 
control of adaptive immunity during obesity. Eight weeks of HFD correlates with major 





 adipose tissue T cell populations (50; 109; 110). Ccr7
–/–
 mice had fewer ATDCs 
and showed metabolic improvement after eight weeks of HFD which suggests that ATDC 





 T cell populations were actually increased in Ccr7
–
/–
 mice which indicate metabolic improvement was not due to reduced T cell numbers in 
the relative absence of ATDCs. Ablation of CD11c
+
 cells has been found to improve 
glucose intolerance partially by deactivating T cells in adipose tissue (142). Whether this 
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is due to alterations in ATMs, ATDCs, or both will have to be examined in future studies. 
We have previously shown that ATMs are required for T cell activation in adipose tissue 
using LysM-Cre mice, but the results from this current study indicate that we can’t 
eliminate the possibility of ATDCs contributing to this effect. ATDCs and ATMs may 
independently direct adaptive immune responses during obesity given the potent antigen 
presentation capabilities of both populations (122; 142). 
Our observation of protection from insulin resistance in Ccr7
–/–
 mice agrees with 
recent reports and identifies loss of the ATDC population as a primary mechanism for 
this effect (162). CCR7 was identified in a module of signal transduction genes that were 
downregulated with weight loss after bariatric surgery that was disconnected from T cell 
signaling genes (163). The functional profile of ATDC in the setting of obesity may be 
strikingly different from that of CD11c
+
 ATM. Unlike ATM, lysosomal and lipid storage 
are not induced in ATDC with obesity. Instead, pathways related to antigen presentation 
and cytokine signaling remain elevated in ATDC suggesting that they have an 
independent contribution to the adipose tissue immune activation environment.   
The protective effect of Ccr2 deficiency in adipose tissue inflammation has been 
supported by several studies (159; 164; 165). However, separating the defects in 
circulating monocytes in Ccr2
–/–
 mice from the defects in migration into peripheral 
tissues in this model is a challenge (166). Our competitive bone marrow experiments 
demonstrate that Ccr2
+/+
 monocytes have an advantage for recruitment from the 
circulation into adipose tissue compared to Ccr2
–/–
 monocytes independent of effects on 
the quantity of circulating monocytes. This supports findings showing CD11c
+
 ATM 
recruitment is CCR2-dependent. Our results also suggest that some conventional ATDC 
are recruited to adipose tissue by CCR2-dependent mechanisms as well. However, the 
relative CCR2-dependency was much lower for ATDC recruitment and suggests that 
ATDC are not likely monocyte derived. ATDC accumulation may instead be dependent 
on recruitment of pre-DC populations from the circulation or proliferation in situ.   
Overall, our studies clarify the somewhat confusing literature on CD11c 
expression in adipose tissue myeloid cells. We propose that there are three primary 





















 ATDCs that 
are predominantly CD11b
+
 conventional ATDC. Importantly, these observations extend 
to human adipose tissue and help inform future studies. ATDCs are not a minor 
population and can be as numerous as ATMs depending on the depot. The elevated 
number of ATDCs in human subcutaneous adipose tissue may explain the lower 
inflammatory capacity of this depot. Whether or not human subcutaneous ATDCs are 
similar in function to human omental ATDCs will be examined in future studies. An 
additional limitation is the lack of samples from lean individuals for comparison and that, 
too, is the topic of ongoing studies by our group. Clarifying the landscape of functional 
antigen presenting cells in adipose tissue may advance our understanding of the 







Table 4 – Antibodies used for flow cytometry this chapter 
Antibody Clone Company 
Anti-mouse   








X54-5/7.1 BD Biosciences 




MR5D3 AbD Serotec 
Siglec-F 






































Table 5 – Sequences for RT-PCR primers used in this chapter 
Gene Primer Sequence 
Arbp 
Forward AGA TTC GGG ATA TGC TGT TGG C 
Reverse TCG GGT CCT AGA CCA GTG TTC 
18S 
Forward TTG ACG GAA GGG CAC CAC CAG 
Reverse GCA CCA CCA CCC ACG GAA TCG 
Flt3 
Forward GAG CGA CTC CAG CTA CGT C 
Reverse ACC CAG TGA AAA TAT CTC CCA GA 
Mertk 
Forward CAG GGC CTT TAC CAG GGA GA 
Reverse TGT GTG CTG GAT GTG ATC TTC 
Camk1 Forward AAG CAG GCG GAA GAC ATT AGG 
Reverse AGT TTC TGA GTC CTC TTG TCC T 
Zbtb46 Forward AGA GAG CAC ATG AAG CGA CA 
Reverse CTG GCT GCA GAC ATG AAC AC 
Fcgr1 
Forward AGG TTC CTC AAT GCC AAG TGA 
Reverse GCG ACC TCC GAA TCT GAA GA 
kit 
Forward GCC ACG TCT CAG CCA TCT G 
Reverse GTC GCC AGC TTC AAC TAT TAA CT 
Ccr7 
Forward TGT ACG AGT CGG TGT GCT TC 
Reverse GGT AGG TAT CCG TCA TGG TCT TG 
Itgax 
Forward CTG GAT AGC CTT TCT TCT GCT G 
Reverse GCA CAC TGT GTC CGA ACT C 
Ccl2 
Forward TTA AAA ACC TGG ATC GGA ACC AA 
Reverse GCA TTA GCT TCA GAT TTA CGG GT 
Il6 
Forward TAG TCC TTC CTA CCC CAA TTT CC 
Reverse TTG GTC CTT AGC CAC TCC TTC 
Ifng 
Forward ATG AAC GCT ACA CAC TGC ATC 
Reverse CCA TCC TTT TGC CAG TTC CTC 
Foxp3 
Forward CCC ATC CCC AGG AGT CTT G 




Chapter 3 – Macrophage Proliferation Sustains Adipose Tissue Inflammation in 
Formerly Obese Mice 
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Abstract 
Obesity causes dramatic pro-inflammatory changes in the adipose tissue immune 
environment, but relatively little is known regarding how this inflammation responds to 
weight loss.  To understand the mechanisms by which meta-inflammation resolves during 
weight loss (WL), we examined adipose tissue leukocytes in mice after withdrawal of 
high-fat diet. After 8 weeks of WL, mice achieved similar weights and glucose tolerance 
as age-matched lean controls but showed abnormal insulin tolerance. Despite fat mass 
normalization, total and CD11c
+
 adipose tissue macrophage (ATM) content remained 
elevated in WL mice for up to 6 months and was associated with persistent fibrosis in 
adipose tissue. ATMs, but not adipose tissue dendritic cells, in formerly obese mice 
demonstrated a pro-inflammatory profile including elevated expression of IL-6, TNFα, 
and IL-1ß. T cell deficient Rag1
–/–
 mice showed a similar degree of ATM persistence as 
WT mice, but with reduced inflammatory gene expression. Proliferation was identified as 
the predominant mechanism by which ATMs are retained in adipose tissue with WL. Our 
study suggests that weight loss does not completely resolve obesity-induced ATM 
activation which may contribute to the persistent adipose tissue damage and reduced 






Obesity induces a state of chronic low-grade inflammation characterized by 
qualitative and quantitative changes in the leukocytes of metabolic tissues including the 
hypothalamus, liver, and adipose tissue (98; 167; 168). In particular, inflammation within 
visceral adipose tissue of obese mice and humans has been shown to be associated with 
diabetes and contribute to the development of insulin resistance, with multiple cellular 
sources contributing to the inflammatory environment including adipocytes, stromal cells 
and leukocytes (113; 114). In mice, a pro-inflammatory CD11c
+
 macrophage population 
accumulates in visceral adipose tissue during obesity and assumes a metabolically 
activated phenotype that is associated with development of systemic insulin resistance 
(51; 137; 138). Recruitment of circulating bone marrow-derived monocytes as well as 
proliferation contribute to CD11c
+
 adipose tissue macrophage (ATM) accumulation and 
maintenance (124; 159; 169). Adipose tissue T (ATT) cell-dependent signals have also 
been shown to promote CD11c
+
 ATM accumulation and inflammation with obesity (109; 
112). 
While there is a fairly detailed understanding of how adipose tissue inflammation 
is generated with obesity, relatively few details are known regarding how adipose tissue 
leukocytes respond to weight loss following obesity. Previous studies have shown 
varying degrees of change in adipose tissue inflammation after weight loss through 
different regimens. Interventions such as caloric restriction or bariatric surgery can 
improve metabolic dysfunction and reduce markers of inflammation within adipose tissue 
(170-172). However, several studies suggest that weight loss may not fully resolve 
adipose tissue inflammation and insulin sensitivity. Inflammation-related gene expression 
in subcutaneous adipose tissue of formerly obese human subjects remains high compared 
to lean individuals (126; 129).  Similar results have been observed in mice where weight 
loss has been shown to be associated with a persistent expression of inflammatory 
cytokines such as IL-6, IL-1β and TNFα in adipose tissue (125; 130; 173; 174). Schmitz 
et al recently demonstrated weight loss improved glucose tolerance but incompletely 
resolved adipose tissue inflammation and insulin sensitivity in mice and humans (125). 
Few studies have specifically examined how weight loss influences the quantity and 
quality of adipose tissue leukocytes. Weight cycling in mice suggests IFNγ-expressing T 
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cells accrue during successive high-fat diet exposures indicating an incomplete resolution 
of lymphocyte activation with weight loss (175). Weight loss has also been shown to 
induce short term ATM recruitment in response to lipolytic signals (176). 
Understanding the cellular and molecular events that reshape adipose tissue 
leukocytes during the resolution of obesity may identify pathways important in 
promoting weight loss and improvements in insulin resistance. Therefore, our objective 
was to perform a detailed investigation into the effects of weight loss on inflammatory 
leukocyte activation and composition within adipose tissue to understand the mechanisms 
by which metabolic inflammation may resolve. We found weight loss improved glucose 
tolerance, however abnormal systemic and visceral adipose tissue insulin resistance 
persisted. This was associated with long-term alterations in the composition of adipose 
tissue leukocytes including retention of proliferating CD11c
+
 ATMs, expansion of 
adipose tissue lymphocytes, and a persistent activation state of ATMs despite weight loss. 
Understanding which inflammatory characteristics of obesity remain despite weight loss 
helps inform our understanding of the relationship between adipose tissue inflammation 
and metabolic function. 
 
Materials and Methods 
Animals and Animal Care 
Male Rag1
–/–
 (B6.129S7-Rag1tm1Mom/J) and C57BL/6J mice were purchased 
from Jackson Laboratory.  Mice were started at 6 weeks of age on control diet (LabDiet 
PicoLab 5L0D 4.09kcal/gm 29.8% protein, 13.4% fat, 56.7% carbohydrate) or high-fat 
diet (Research Diets D12492, 5.24kcal/gm 20% protein, 60% fat, 20% carbohydrate).  
Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed 
after 6 hour fasting. Mice were injected IP with D-glucose (0.7 g/kg) for GTTs and 
human recombinant insulin (1 U/kg) for ITTs. Insulin and Leptin measured by ELISA 
(Crystal Chem). Energy metabolism was measured using Comprehensive Lab Animal 
Monitoring System analysis (CLAMS, Columbus Instruments) and body composition 
measured by NMR (Minispec LF90II, Bruker Optics). All mice procedures were 
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approved by the University of Michigan Committee on Use and Care of Animals and 
were conducted in compliance with the Institute of Laboratory Animal Research Guide 
for the Care and Use of Laboratory Animals. 
 
Isolation of Adipose Tissue SVF and Flow Cytometry 
Excised adipose tissue was digested in RPMI with 0.5% BSA and 1 mg/ml type II 
collagenase for 25 min at 37 °C and the stromal vascular fraction was separated from 
adipocytes by centrifugation. The following antibodies were used for flow cytometry: 
anti-CD45 (30-F11), anti-CD3e (145-2C11), anti-CD4 (GK1.5), anti-CD8a (53-6.7), anti-
Foxp3 (FJK-16s), anti-IFNγ (XMG1.2), anti-Ki67 (SolA15), anti-TNFα (MP6-XT22), 
anti-CD40 (1C10), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-CD11c (N418)  
(eBioscience), anti-IL-6 (MP5-20F3) and CD64 (X54-5/7.1) (BD Pharmingen). Analysis 
was performed on a BD FACSCanto II and sorting was performed on a FACSAria III 
(BD Biosciences). 
 
Gene expression analysis and microarray 
RNA was extracted from adipose using Trizol LS (Life Technologies) and cDNA 
generated using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
SYBR Green PCR Master Mix (Applied Biosystems) and the StepOnePlus System 
(Applied Biosystems) were used for real-time quantitative PCR. Gapdh expression was 
used as an internal control for data normalization. Samples were assayed in duplicate and 
relative expression was determined using 2
−Δ Δ
 CT method. For microarray experiments, 
analysis was done using Mouse Gene ST 2.1 plate and WT-Pico kit (Affymetrix, Santa 
Clara, CA). Expression values were calculated using a robust multi-array average. Data 
were filtered to remove probesets with a variance over all samples of less than 0.1 and 
then fit to a linear model (177; 178). The false discovery rate was set at an adjusted P 
value of 0.05. Oligo_1.24.2 and limma_3.16.7 packages from Bioconductor were used 
for data analysis in the R statistical environment (R version 3.0.0 2013-04-03).  
55 
 
Primer sequences used for this study are provided in Table 6. 
 
Immunoblotting 
Adipose tissue was homogenized in RIPA lysis buffer with phosphatase inhibitors 
(Roche). Protein concentration was determined using Bio-Rad Protein Assay Dye 
Reagent. Proteins were labeled and visualized using Odyssey infrared imaging system 
(Li-Cor Bioscience). Antibodies used for immunoblotting: anti-PPARγ(81B8), anti-IRS-
1, anti-Phospho-Akt (Ser473), anti-AKT, anti-Adiponectin(C45B10), anti-
Caveolin(D46G3) (Cell Signaling Technology)  and anti-β-Actin(AC-40) (Sigma-
Aldrich).  
 
Glycerol Release, Collagen Quantification and Cytokine Array 
Stimulated release of glycerol was performed on minced 100mg pieces of adipose 
cultured five hours ± isoproterenol (1μM) according to manufacturer’s instructions for 
Glycerol Detection Kit for Explants (ZenBio). Explants were cultured in serum-free AIM 
V media with AlbuMax and BSA (Life Technologies). Additional samples were 
hydrolyzed in 6M HCl according to manufacturer’s instructions for Total Collagen Assay 
Kit (Cedarlane Labs, QuickZyme BioSciences).  Culture supernatant glycerol and 
adipose hydroxyproline content was measured using colorimetry. Mouse Cytokine 
Antibody Array (R&D Systems) was used to evaluate cytokine output from adipose 
tissue explants after 48 hours and pooled from 3 samples. Quantitation by ImageJ after 
background subtraction and normalization to reference controls. 
 
Immunohistochemistry and Immunofluorescence 
Ki67 IHC and H&E sections were performed by the University of Michigan’s 
Comprehensive Cancer Center Histology Core. Picosirius red stain kit was used 
following kit manufacturer instructions (Polysciences Inc). Antibodies used for 
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immunofluorescence include: polyclonal anti-caveolin (BD Pharmingen) and anti-Mac2 
(Galectin-3) (eBioM3/38) (eBioscience). 
 
PKH26 labeling of macrophages in vivo 
PKH26 cell linker kit for phagocytic cell labeling (Sigma-Aldrich) was used for in 
vivo macrophage labeling experiments per manufacturer instructions. Briefly, 500μl of a 
1μM solution of PKH26 dye mixed with diluent was injected into two sets of ND and 12 
week HFD fed mice intraperitoneally before weight loss. The first set was euthanized one 
day later to check labeling efficiency and the second set after weight loss (8wk); PKH26 
uptake was evaluated using flow cytometry.  
 
Statistical Analyses 
All values are reported as mean ± SEM unless otherwise noted. Statistical 
significance of differences between ND controls and other diet groups were determined 
using unpaired two-tailed Student’s t-test or one-way ANOVA for multiple groups with 
Fisher’s least significant difference test for planned statistical comparisons, unless 





Figure 3-1 – Glucose tolerance normalization but persistently elevated insulin with weight 
loss. (A) Cartoon showing obesity induction and weight loss model. (B) Body weight curve after 
weight loss (n ≥ 12 ND, n ≥ 16 WL). (C) Adipocyte-size distribution and average adipocyte size. 
(D) Fat weight curve after weight loss (n = 4).  (E) Fasted blood glucose and glucose tolerance 
after weight loss (n ≥ 4, # refer to HFD vs ND). (F) Fasted serum insulin (n ≥ 4) and insulin 
tolerance after weight loss (n = 4, $ refer to HFD versus ND while * refer to WL versus ND). (G) 
Fasted serum leptin concentrations (n = 8). H and I: Food intake measures (H) and energy 
expenditure (I) (n = 4). 
#,*
p < 0.05, 
##,**
p < 0.01, 
***
p < 0.001, 
####,****
p <0.0001; significance 





Withdrawal of high-fat diet decreases adiposity and improves glucose tolerance but not 
insulin tolerance in mice 
We established a model of weight loss based on the withdrawal of high-fat diet 
(HFD). Male C57BL/6J mice were fed high-fat diet (HFD 60% kcal fat) or normal diet 
(ND, 13.5% kcal fat) for 12 weeks. Obese mice were then either maintained on HFD or 
switched to ND to induce weight loss over a period of 2-24 weeks (Figure 3-1A). After 8 
weeks diet-switch, body weight of weight loss (WL) mice decreased ~28% from 44.8g 
(SD ± 2.8) to 31.8g (SD ± 2.3) and was similar to age-matched ND fed mice (29.6g (SD 
± 1.8) (Figure 3-1B). Body composition analysis showed no significant differences in 
percentage fat and lean mass between ND and WL mice (data not shown). Epididymal 
(eWAT) and inguinal (iWAT) white adipose tissue mass and eWAT adipocyte size 
normalized by 4 weeks off HFD (Figure 3-1D, 3-1C).   
To assess metabolism after weight loss, GTTs and ITTs were performed. After 8 
weeks of weight loss fasting glucose and glucose tolerance decreased to levels similar to 
ND mice (Figure 3-1E). Fasting serum insulin levels decreased, but remained elevated 
compared to ND controls (Figure 3-1F). ITTs revealed improvement in insulin sensitivity 
in WL mice compared to HFD, but insulin tolerance remained abnormal compared to ND 
mice (Figure 3-1F). Leptin levels were lower in WL mice compared to HFD, but 
remained elevated compared to ND (Figure 3-1G). Food intake and energy expenditure 
increased in WL mice compared to HFD mice, but remained lower than ND fed controls 
(Figure 3-1H-I). The respiratory exchange ratios for ND and WL mice were not 
significantly different, and were both higher than HFD mice. No differences in physical 
activity were noted between groups. Overall, these studies demonstrated that formerly 
obese mice retained persistent abnormalities in insulin sensitivity despite normalization 




Figure 3-2 – Epididymal adipose tissue maintains features associated with obesity despite 
weight loss. (A) Immunofluorescence and H&E stained epididymal adipose (eWAT) slides 
representative for each diet condition showing CLS development and maintenance. (B) 
Picrosirius red staining of eWAT slides representative of diet conditions. (C) Hydroxyproline 
quantification of eWAT (n ≥ 4). (D) Isoproterenol stimulated glycerol release from whole eWAT 
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explants (n = 8). (E) eWAT explant multiplex cytokine array (n=2 per condition).  (F) 
Quantification of densitometry measurements from immunoblots of whole eWAT (n = 2 ND, n = 
4 HFD & WL; ANOVA with Dunnet’s multiple comparisons. (G) Representative immunoblots 
from mice injected IP with or without 1U/kg insulin for 10 minutes with 2 mice pooled per lane. 
(H) Phosphorylated AKT s473 relative to total AKT from immunoblots (n = 2 for baseline and n 
= 3 for insulin administered = +insulin). 
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001, 
****
p < 0.0001; 
significance compares with the ND-fed control group. 
 
Measures of adipose tissue dysfunction persist despite weight loss after HFD 
We next evaluated if adipose tissue structure normalized with weight loss 
concomitant with the normalization of depot mass. Crown-like structures (CLS), a 
characteristic histologic feature of obese adipose tissue, were induced with 12 weeks of 
HFD. Despite weight loss CLS remained a prominent feature of eWAT and were similar 
in quantity to mice maintained on HFD for 20 weeks (Figure 3-2A). Picrosirius red 
staining demonstrated an association between CLS persistence and adipose tissue fibrosis 
in WL mice (Figure 3-2B).  Biochemical quantification of hydroxyproline content in 
adipose tissue supported this finding of increase fibrosis (Figure 3-2C).  
We next examined several measures of adipocyte function in WL mice. To assess 
lipolysis, explant baseline glycerol release was examined and found to be similar between 
ND, 20wk HFD and 8wk WL explants (Figure 3-2D). Isoproterenol-stimulated glycerol 
release was decreased in HFD mice compared to ND mice and was restored after weight 
loss. Cytokine release was assessed in eWAT explants by cytokine arrays (Figure 3-2E).  
Adipose tissue secretion of CCL3, CCL4, CCL5, and CXCL9 was increased in WL 
eWAT compared to HFD. IL-1RA and CCL12 were increased in both HFD and WL mice 
compared to ND mice. 
Immunoblots demonstrated decreases in PPARγ, IRS-1, and total Akt protein 
expression in eWAT from HFD and WL mice compared to ND (Figure 3-2F-G). 
Caveolin and 27kDa adiponectin were similar between groups.  Adipose AKT serine 473 
phosphorylation (pAKT) was decreased in HFD and WL mice at baseline (Figure 3-2G-
H), but pAKT in WL mice was not significantly different from ND mice after insulin 
injection. Overall, these data demonstrate that formerly obese mice demonstrate 
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persistent derangements in adipose tissue architecture, fibrosis, adipogenic protein 
expression, and cytokine production. 
 
ATMs maintain a pro-inflammatory profile despite weight loss 
Flow cytometry was used to profile adipose tissue leukocyte changes with weight 
loss. The percentage of CD45
+
 cells in the stromal vascular fraction (SVF) of eWAT was 
increased with HFD.  WL mice had fewer CD45
+
 leukocytes in the SVF than HFD mice 





 (179)) were reduced with weight loss, but remained significantly 
elevated compared to ND when expressed as either total ATM per eWAT pad, ATMs per 
gram eWAT or as a frequency of CD45
+
 leukocytes (Figure 3-3B-D). While total ATM 
content was reduced with weight loss, the frequency of CD11c
+
 ATMs remained 
consistently elevated (Figure 3-2E), indicating that formerly obese mice have long-term 
perturbations in ATM composition. 
During obesity, CD11c
+
 ATMs express a pro-inflammatory gene expression profile (49; 
138). To see if CD11c
+
 ATMs from WL mice retained pro-inflammatory characteristics, 
FACS sorted ATMs were evaluated using gene expression microarrays. Microarrays 
revealed that all ATMs during obesity and after weight loss, regardless of CD11c (M1-
like marker) or CD301 (M2-like marker) expression, had similar gene expression profiles 
and were thus combined for the following analyses. Pathway analysis identified 
enrichment of genes involved in Cytokine-Cytokine Receptor Interaction (mmu04060) 
and Chemokine Signaling Pathway (mmu04062) in ATMs from WL mice compared to 
ND mice (180). WL ATMs maintained a pro-inflammatory expression profile compared 
to ND mice including increased Il-1β, Il-6, Tnfα, Cxcl1, Ccl4, Ccl5, Ccl11 and Ccl12 
(Figure 3-3F).  Intracellular cytokine labeling of non-stimulated ATMs verified increased 
IL-6 (Figure 3-3G) and TNFα (Figure 3H) protein expression despite weight loss. 
Immunofluorescence localization of active IL-1β revealed enrichment surrounding CLS 
in HFD mice that was sustained after weight loss (Figure 3-3I).  Overall this 
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demonstrates a persistence of pro-inflammatory ATMs in WL mice and suggests that 
weight loss is insufficient to deactivate ATMs.  
 
Adipose tissue physiologic and immune cell perturbations persist as long as six months 
off high-fat diet 
To establish how long the effects of obesity might persist in adipose tissue after 
weight loss, we extended our weight loss model to 24 weeks off HFD. Body weights in 
24wk WL mice were 35.8g (SD ± 1.3) compared to HFD at 60.8g (SD ± 4.3) and ND 
mice at 32.8g (SD ± 1.2) (Figure 3-4A), while eWAT weight completely normalized 
(Figure 3-4B). Total ATM and CD11c
+
 ATM content remained significantly elevated 
compared to ND and comparable to 8wk WL mice (Figure 3-4C-D). Overall the data 
indicate prolonged maintenance of leukocyte population changes induced by obesity 
despite weight loss. Immunofluorescence revealed continued maintenance of CLS 
(Figure 3-4F). However, H&E staining revealed these CLS were surrounded by less 
dense collagen deposition than CLS found in 8wk WL mice. 24wk WL mice also no 
longer retained the abnormal systemic insulin responsiveness (Figure 3-4E) observed in 
8wk WL mice. 
We next evaluated if the degree of ATM persistence is dependent on the duration 
of HFD exposure prior to diet switch. Mice were placed on HFD for 6, 9 or 12 weeks 
prior to switching to ND for 8 weeks. All HFD groups gained weight (6wk: 37.45g SD ± 
3.5, 9wk: 38.6g SD ± 3.6, and ND: 23.67 SD ± 0.9), but 6wk and 9wk HFD groups 
gained less than 12wk HFD mice (46.6g ± 2.0) (Figure 3-4G). After weight loss, eWAT 
weights in all HFD durations were similar to ND controls (Figure 3-4H). Total ATM 
content after weight loss was higher than age-matched ND mice and increased with 
longer time spent on HFD (Figure 3-4I). CD11c
+
 ATMs after weight loss in 6wk and 9wk 
HFD mice remained slightly increased compared to ND controls (Figure 3-4J).  However, 
mice fed HFD for 12 weeks prior to weight loss had significantly more CD11c
+
 ATMs 
after weight loss than the groups exposed to HFD for shorter times. Immunofluorescence 
after weight loss revealed fewer CLS in 6wk HFD and 9wk HFD mice (Figure 3-4K) 
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compared with 12wk HFD (Figure 3-2A). These data indicate that the degree to which 
ATMs and CD11c
+
 ATMs persist in adipose tissue after weight loss is dependent on the 
duration of HFD or degree of adiposity prior to weight loss intervention. 
 
Weight loss does not alter ATM in inguinal adipose tissue and improves liver steatosis 
Subcutaneous inguinal white adipose tissue (iWAT) was also evaluated to 
determine how this adipose tissue depot responds to weight loss. iWAT weights remained 
significantly elevated after weight loss compared to ND mice (Figure 3-5A). WL mice 
had fewer CD45
+
 leukocytes in iWAT than HFD mice and were similar to ND (Figure 3-
5B). Total ATMs trended towards being increased in HFD and WL mice but were not 
significantly different from ND (Figure 3-5C). The frequency of all ATMs and CD11c
+
 
ATMs were not increased in HFD or WL mice compared to ND (Figure 3-5D-E). 
Histology revealed little or no CLS and fibrosis in iWAT of HFD or WL mice (Figure 3-
5F). Overall the results indicate immune infiltration to murine iWAT during obesity is 
blunted compared to eWAT and remains low with weight loss. Liver histology revealed 





Figure 3-3 – Maintenance of inflammatory CD11c
+ 
adipose macrophages despite weight 











) gating strategy. (B) Total ATM content per eWAT pad (left) and ATM 
content per gram of eWAT (right) (n = 4). (C) Frequency of CD45
+
 immune cells of all eWAT 
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SVF (n ≥ 4). (D) Frequency of CD64
+
 ATM of all CD45
+
 SVF (n ≥ 4). (E) Frequency of CD11c
+
 




 ATM (n ≥ 4). (F) Gene expression of select immune genes from 
microarrays of flow sorted ATMs (two-way ANOVA with Dunnett’s multiple comparisons, α = 
0.05). #Significance comparing WL to HFD groups. Intracellular cytokine staining of 
unstimulated SVF showing (G) IL6 protein expression and (H) TNFα protein expression from 
eWAT ATM (n = 4). (I) Immunofluorescence from eWAT showing cleaved IL1β deposition 
surrounding CLS in mice during obesity and after weight loss. 
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001 
and 
****
p < 0.0001; significance compares with the ND-fed control group unless otherwise 
indicated 
 
Increased IFNγ production potential of adipose T cells after weight loss 
Cross-talk between macrophages and T cells is critical for the activation of both 
cell types in obesity (142; 181). We evaluated co-stimulatory marker expression on 
eWAT ATMs from WL mice. Relative to the ND control group, Cd40 expression is 
reduced in ATMs sorted from HFD mice but increased in ATMs from WL mice (Figure 
3-6A). Weight loss induced Cd80 expression in ATMs (Figure 3-6B) while Cd86 was 
reduced in both HFD and WL ATMs compared to ND controls (Figure 3-6C).  Surface 





ATMs were significantly higher in WL mice compared to ND mice, while CD86
+
 ATMs 
were elevated in both ND and WL mice (Figure 3-6D).  
We next investigated how weight loss influenced adipose tissue T cells (ATT).  
Similar to ATMs, conventional CD4
+
 T cell and CD8
+
 T cell numbers increased with 
obesity (Figure 3-6E). CD4
+ 
ATT cells decreased after 2 weeks and transiently increased 
4 weeks after diet switch. CD8
+
 ATT cells were decreased in WL mice, but remained 
significantly elevated compared to ND up to 8 weeks after diet switch (Figure 3-6F). 
Total Foxp3
+
 regulatory ATT cell numbers were also increased with obesity and returned 







Figure 3-4 – Obesity-induced effects can persist in adipose as long as six months after HFD 
removal. (A) Body weight and (B) eWAT weight of mice after 24 weeks of WL along with 




 ATM content per eWAT pad for six-month 
weight loss mice (n = 4). (D) Frequency of CD11c
+




 ATM (n = 4). (E) 
GTT (n = 4, #Significance compares HFD with ND).  (F) Immunofluorescence and hematoxylin 
& eosin stained slides representative for each diet condition showing CLS development and 
maintenance. (G) Body weight and (H) eWAT weight of mice after weight loss from 6, 9 or 12 




 ATM content per eWAT pad for 
short-term HFD fed mice (n = 4). (J) Frequency of CD11c
+




 ATM (n = 
4). H-J ANOVA with Tukey multiple comparisons (α = 0.05) was used to compare WL averages 
to each other and to the ND-fed group; HFD points were not included in analysis. (K) 





p < 0.01, 
***
p < 0.001 and 
$$$$,****
p < 0.0001; significance compares with the ND-fed 
control group unless otherwise indicated 
 
Obesity promotes type-1 polarization of T cells within adipose tissue and IFNγ 
has been implicated in the development of insulin resistance (111; 182-184). Evaluation 
of IFNγ
 









 ATTs in HFD compared to ND mice (Figure 3-6H-I). 










 ATT cells returned to ND levels after 4 weeks of weight loss and was 





ATT cells occurs in adipose tissue in the setting of weight loss. 
 
T cells contribute to ATM activation with weight loss, but are not required for 
macrophage accumulation 
Given the increase in ATT with weight loss, we evaluated if T cells were required 
for the persistence of ATMs in formerly obese mice. T and B cell deficient Rag1
–/–
 mice 
and WT controls were fed HFD for 12 weeks and then switched to ND (Figure 3-7A). 
Rag1
–/–
 mice weighed less than WT mice prior to diet switch.  Surprisingly, Rag1
–/– 
WL 
mice had significantly worse glucose tolerance compared with Rag1
–/–
 ND controls 
despite similar body weights (Figure 3-7B) which contrasts with the normalized GTTs of 
WT WL mice (Figure 3-1E). Similar to WT mice, Rag1
–/– 





 ATMs despite 8 weeks of weight loss (Figure 3-7C-D). Crown-like 
structures persist in WT and Rag1
–/–
 WL mice as assessed by histology (Figure 3-7H-I 
and 3-8A). 
 
Figure 3-5 – Inguinal adipose tissue and liver changes with weight loss. (A) Inguinal white 
adipose tissue (iWAT) weights. (B) Frequency of CD45
+





ATM in iWAT. (D) Frequency of ATM of all CD45
+ 
iWAT SVF leukocytes. 
(E) Frequency of CD11c
+
 cells of all ATM (n = 4 for A-E). (F) H&E stained iWAT and (G) liver 
slides. 
**
p < 0.01 and 
****






Figure 3-6 – Adipose tissue T cell activation with weight loss. Quantitative RT-PCR from flow 
sorted ATMs of mice evaluating (A) CD40, (B) CD80 and (C) CD86 gene expression (ATMs 
pooled from a total of 12 mice from the ND and HFD groups and 6 mice from the WL group;  
ND n = 4, HFD n = 4, WL n = 2). (D) Surface marker expression of Cd40, Cd80, and Cd86 
evaluated by flow cytometry (n = 4). Total ATT cell count per eWAT pad evaluated by flow 
cytometry for (E) conventional CD4
+
 T cells, (F) CD8
+




 T regulatory 
cells (n ≥ 4 for E-G).  Intracellular cytokine stain on phorbol myristic acetate and ionomycin 
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stimulated SVF to evaluate IFNγ production potential from (H) CD4
+





p < 0.05, 
**
p < 0.01, 
***
p < 0.001, 
****
p < 0.0001; significance compares with the ND-fed 
control group. 
 
Figure 3-7 – T cells are not required for CD11c
+
 macrophage accumulation but may control 
inflammatory activation state. (A) Body weight curves during weight loss (n ≥ 4). (B) Glucose 
tolerance in Rag1
–/–
 knockout mice after weight loss (left) and normalization of total body weight 




 ATM content per eWAT pad for Rag1
–/–
 mice (n ≥ 4). (D) 
Frequency of CD11c
+




 ATM (n ≥ 4). Quantitative RT-PCR from flow 
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sorted ATMs evaluating (E) Il6, (F) Tnfα and (G) Il1β gene expression (ATMs pooled from a 
total of 12 mice from the ND and HFD groups and 6 mice from the WL group; WT ND n = 4, 
WT HFD n = 4, WT WL n = 2, Rag WL n = 4. (H) H&E stained slides and (I) 
immunofluorescence representative images showing CLS development and maintenance despite 
weight loss. 
*
p < 0.05, 
**
p < 0.01 and 
****
p < 0.0001; significance compares with the ND-fed 
control group unless otherwise indicated. 
 
To evaluate the contribution of T and B cells towards ATM pro-inflammatory 
activity during weight loss, we assessed gene expression from flow sorted ATMs in WT 
and Rag1
–/–
 WL mice. Il6, Tnfa and Il1b were all increased in HFD-fed Rag1
–/–
 mice, but 
were significantly reduced in Rag1
–/–
 WL mice compared to WT WL mice (Figure 3-7E-
G). Rag1
–/–
 adipose insulin signaling was evaluated. Relative to ND mice, baseline pAKT 
was decreased in Rag1
–/–
 WL mice. However, similar to WT mice, pAKT was not 
significantly different from ND mice after insulin injection in Rag1
–/–
 WL mice (Figure 
3-7J). Given the accumulation of CLSs and fibrosis in Rag1
–/– 
mice during obesity and 
weight loss (Figure 3-7H-I and Figure 3-8A), we decided to further investigate 
adipogenic gene and protein expression in whole eWAT tissue. Analysis revealed similar 
gene expression profiles between WT and Rag1
–/– 
mice during obesity and weight loss 
for all genes evaluated (Figure 3-8B). Immunoblots revealed reduced protein expression 
for IRS1, PPARγ, and AKT in Rag1–/– mice during HFD feeding (Figure 3-8C-D). 
Similar to WT eWAT tissue, expression of these proteins were reduced with HFD and 
remained significantly reduced despite weight loss in Rag1
–/–
 mice. Taken together, the 
data show that T cells are not essential for the maintenance of CD11c
+ 
ATMs or the 
continual development of adipose derangement with weight loss in WT mice. However, 
signals from lymphocytes appear to contribute to the ongoing pro-inflammatory 
activation of ATMs in formerly obese mice. 
 
ATM after weight loss are derived primarily from macrophages present during obesity 
and maintained through proliferation 
We next examined the mechanisms responsible for ATM persistence during 
weight loss. To determine if recruitment was a significant contributor to ATM 
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maintenance during weight loss, we employed PKH26 pulse-labeling in ND and HFD 
mice prior to diet switch. This method labels tissue macrophages, but not blood 
monocytes, allowing identification of recruited ATMs as PKH26
–
 cells (49). Twelve-
week HFD and ND controls were injected IP with PKH26. Labeling efficiency of ATMs 
assessed one day after PKH26 injection was similar in lean and obese mice (Figure 3-9A-
B). The frequency of PKH26
+
 ATMs was examined after 8 weeks and was lower in ND 
mice compared to HFD or WL groups demonstrating a higher rate of ATM retention in 
HFD and WL mice (Figure 3-9C). The data indicate that new monocyte recruitment may 
not be the primary mechanism for maintenance of CD11c
+
 ATMs during weight loss. 
Reduced apoptosis was also considered as a potential mechanism of ATM 
maintenance. ATM annexin V labeling was significantly reduced in HFD mice and after 
one week of diet-switch compared to ND mice indicating these ATMs had a relatively 
low level of apoptosis which may contribute to ATM maintenance in eWAT of HFD and 
WL mice (Figure 3-9D). This is surprising given the reduction in total ATM content 
observed during the early stages of weight loss (Figure 3-3D) and suggests ATM 
exfiltration may be responsible for the decrease. 
Another mechanism for how total numbers of ATMs may be sustained without 
continual recruitment is proliferation. We evaluated ATM proliferation by Ki67 
expression. IHC demonstrated an increase in Ki67
+
 nuclei surrounding CLS in 8wk WL 
mice compared to 12wk HFD and comparable to 20wk HFD mice (Figure 3-9E-F) 
suggesting a continual increase in proliferating cells despite WL. Flow cytometry 
demonstrated that >90% of the Ki67
+
 cells in the SVF were CD45
+
 leukocytes (Figure 3-
9G). ATMs made up >50% of these Ki67
+
 SVF cells in both HFD and WL mice, and 
both were significantly elevated compared with ND controls (Figure 3-9H). The overall 
frequency of Ki67
+ 
ATMs in HFD and WL mice was also significantly higher than ND 









ATMs (Figure 3-9J). Collectively, the data indicate that CD11c
+ 
ATM maintenance 





Adipose tissue dendritic cell dynamics during obesity and weight loss 
We also evaluated adipose tissue dendritic cell populations (ATDC) during 
obesity and weight loss to compare and contrast with ATMs. Similar to ATMs, ATDCs 
accumulate in eWAT with obesity and, though reduced, remain significantly elevated 
after weight loss when compared to ND mice (Figure 3-10A). However, the overall 
number of eWAT ATDCs was substantially less than ATMs during obesity and after 
weight loss. Microarray analysis of sorted eWAT ATDC populations from both ND and 
20wk HFD mice revealed similar expression levels of pro-inflammatory cytokines Il1b, 
Tnf and Il6 (Figure 3-10B). Intracellular cytokine staining was also done with ATDCs 
and showed little to no expression of TNFα and IL6 during obesity and weight loss 
(Figure 3-10C-D), which was in stark contrast to what was observed in ATMs (Figure 3-
3G). Fewer ATDCs expressed surface co-stimulatory markers (Figure 3-10E) compared 
to ATMs (Figure 3-6A-D) as well. A majority of eWAT ATDCs were found to express 
Ki67 during obesity and weight loss (Figure 3-10F). However, ATMs were still found to 
be the dominant Ki67
+
 population within the SVF and the overall frequency of Ki67
+
 




Figure 3-8 – Rag1
–/–
 mice show altered eWAT gene and protein expression during obesity 
and weight loss similar to WT mice. (A) Immunofluorescence images showing CLS 
development in eWAT tissue after 20 weeks HFD and weight loss. (B) Comparison of eWAT 
gene expression between WT and Rag1
–/–
 mice normalized to WT ND. (C) Immunoblots showing 
protein expression changes during obesity and weight loss in whole eWAT tissue and (D) 
quantification of relative densitometry measures from immunoblots. 
*
p < 0.05, 
**





p < 0.0001. For B and D significance compares with the Rag1
–/–





Figure 3-9 – Macrophages are maintained through increased proliferation and reduced 
apoptosis. Mice were injected with PKH26 intraperitoneally after 12 weeks of HFD exposure 





 ATM showing PKH26
+
 cells one day after injection, 8 weeks after injection and a 
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fluorescence minus one control for PKH26. Frequency of PKH26
+
 ATM either (B) one day after 
injection or (C) 8 weeks after injection. (D) Annexin V staining of SVF as evaluated by flow 
cytometry (n = 4). (E) Representative Ki67 immunohistochemistry slides and (F) Quantification 
of Ki67
+
 nuclei surrounding CLS from the IHC images (n ≥ 7). (G) Flow cytometric analysis 
showing frequency of all Ki67
+
 SVF that were CD45
+
 immune cells (n = 4). (H) Frequency of all 
Ki67
+
 cells that were ATMs (n = 4). (I) Frequency of all ATMs that were Ki67
+ 









 (black) ATM as a percent of all SVF (n = 
4). 
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001, 
****
p < 0.0001; significance compares with the ND-fed 






Figure 3-10 – Adipose tissue dendritic cells have a less-inflammatory profile than ATMs 
during obesity and weight loss. (A) Total adipose tissue dendritic cells (ATDC) in eWAT. (B) 
Gene expression as evaluated by microarray on FACS sorted ATDCs from eWAT of lean and 
obese mice. Frequency of ATDCs expressing (C) TNFα and (D) IL6 as determined by flow 
analysis of intracellular cytokine labeled SVF. (E) Surface labeling of co-stimulatory markers on 
ATDCs from eWAT tissue of ND and WL mice. (F) Frequency of all ATDCs which are also 
Ki67
+
 and (G) frequency of all Ki67
+
 SVF that are ATDCs. 
*
p < 0.05, 
***
p < 0.001, 
****
p < 
0.0001; significance compares with the ND-fed control group. 
 
Discussion 
In this study, we used a mouse model of weight loss to understand leukocyte 
dynamics in adipose tissue of formerly obese mice. Our major finding is that chronic 
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obesity leads to long term alterations in adipose tissue leukocyte populations associated 
with persistent abnormalities in insulin tolerance that persist despite weight loss. 
Maintenance of CD11c
+ 
ATMs was observed as long as six months after HFD was 
stopped. ATMs, but not ATDCs, in WL mice retained a pro-inflammatory profile with 
elevated cytokine (IL-6, IL-1β and TNFα) and costimulatory marker expression. Adipose 
tissue T cells were required for ATM activation, but not required for sustaining ATMs in 
abdominal depots. 
ATMs were sustained in formerly obese mice primarily through local 
proliferation and decreased apoptosis and not ongoing recruitment of blood monocytes. 
The mechanism(s) for ATM proliferation induction and maintenance remains unclear at 
this time, but potential mechanisms include MCP-1 and IL-4 (169; 185). Our findings are 
in agreement with other studies suggesting that weight loss only partially improves 
adipose tissue inflammation after it is established (125; 130; 173; 174). The transient 
increase and persistence of CLSs that we observe in this study is more robust than 
reported in other studies. One potential difference is our use of 60% HFD for 12 weeks, a 
widely used model of chronic over-nutrition (48; 49; 51; 87; 112). We found that the 
leukocyte changes observed after removal of HFD were dependent on the duration of 
HFD feeding and, potentially, body fat percentage. We focused on the inflammatory 
activation of individual leukocyte subsets because of a lack of studies comparing the 
activation profiles of sorted ATMs and T cells after weight loss. We observed reduced 
Tnfα and Il1β in WL ATMs compared to ATMs residing in mice maintained on HFD in 
agreement with other observations (51). However, Il6 expression was substantially 
increased and we found the overall expression of inflammatory cytokines and 
chemokines from ATMs remained significantly elevated in WL mice compared to ND 
mice. Overall, our observations significantly support and critically extend an evolving 
paradigm demonstrating that obesity imparts lasting changes which fail to fully resolve 
with weight loss. Clinical studies have found persistent subcutaneous adipose 
inflammation in humans after weight loss despite improvements in insulin sensitivity 
improvements (125; 126; 130; 186). 
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We also observed a persistent decrease in systemic insulin sensitivity in WL mice 
associated with adipose tissue architectural changes, elevated ATM content, and fibrosis 
in agreement with other recent studies (51; 125; 126). Several proteins involved in 
adipocyte differentiation and insulin signaling were substantially reduced in formerly 
obese mice despite return to normal weight. Interestingly, the 24 week weight loss 
experiment shows that adipose tissue fibrosis can be cleared with time (Figure 3-4F). It’s 
worth speculating that retained ATMs may also have beneficial functions related to 
resolving the excess extracellular matrix deposition consistent with the role macrophages 
play in wound healing and matrix remodeling (187; 188). Further investigation is 
necessary to determine whether ATMs have potentially beneficial functions within 
adipose tissue in addition to known deleterious activity.  
Given the connection between antigen presenting cells and T cell activation in 
adipose tissue, we evaluated T cell changes with weight loss (111; 181; 184). Weight 
cycling was shown to alter T cell composition in adipose tissue (175) and we observed 





 T cells, were retained during weight loss. However, experiments in 
Rag1
–/– 
mice revealed that T cells were not required for CD11c
+
 ATM recruitment and 
maintenance. After weight loss, Rag1
–/– 
mice remained glucose intolerant which may 
relate either to ongoing adipose tissue inflammation due to lack of regulatory T cells (50), 
or due to dysfunction in other metabolic tissues such as islets or the liver. Our findings 
also indicate that lymphocyte signals are necessary for the inflammatory maintenance of 
ATMs during weight loss but are not necessary for pro-inflammatory activation of ATMs 
during HFD-induced obesity. This suggests lymphocyte-derived stimulatory signals (i.e. 
CD40L or IFNγ) could be targeted to attenuate inflammation while still preserving 
beneficial ATM functions but that active obesity may limit the potential efficacy. Innate 
lymphocyte populations, such as NK cells, should also be carefully investigated during 
obesity and weight loss to determine how they may influence the adipose tissue 
inflammatory state. It’s also important to note publications which have found potentially 
neutral or even beneficial effects of inflammation for regulating adipose tissue function. 
Thermoneutrality, for example, potentiates adipose tissue inflammation and ATM 
accumulation without abnormalities in glucose regulation (189). Low-level adipose 
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inflammation has even been found to be important for maintaining metabolic homeostasis 
and adipogenesis (87). Overall the literature indicates the role played by adipose tissue 
inflammation is complex with both detrimental and potentially beneficial effects on 
adipose tissue function.  
Clinical studies have shown persistent risk for cardiometabolic disease 
development in formerly obese adults (125; 126; 128). Our study suggests obesity elicits 
damage responses in adipose that persist despite weight loss which may contribute to this 
risk. We posit that maintenance of these features within adipose, particularly 
inflammation, could contribute to the persistence of metabolic disease risk observed in 
formerly obese patients. It will be critical to compare our results obtained from using 
dietary manipulation with the induction of weight loss by other mechanisms such as 
bariatric surgery which may impart different outputs in the inflammatory state of adipose 
tissue (190). A potential weakness of this study is that our weight loss protocol did not 
use isocaloric diets and did not control for food intake by pair-feeding. Our paradigm was 
designed to mimic current weight loss strategies that use reduced calorie diet meal 
replacement to achieve weight loss. We believe this paradigm offered the best potential 
for reversal of obesity-associated features. It’s possible, though we believe unlikely, that 
maintaining HFD but using caloric restriction to induce weight loss may show improved 
resolution. Future work will continue to investigate the physiological consequences of 
these maintained features. In particular, we would be interested in identifying whether 
formerly obese mice have altered physiologic responses in response to certain stimuli 
such as HFD re-challenge. An additional limitation was the inability to evaluate 
additional adipose-resident leukocyte populations, such as B cells and NK cells, which 
may influence the overall inflammatory state of adipose tissue during both obesity and 
weight loss. We hope the results from this study invigorate interest for evaluating 





Table 6 – Sequences for RT-PCR primers used in this chapter. 
Gene Forward Primer Reverse Primer 
Cd40 TGTCATCTGTGAAAAGGTGGTC ACTGGAGCAGCGGTGTTATG 
Cd80 ACCCCCAACATAACTGAGTCT TTCCAACCAAGAGAAGCGAGG 
Cd86 TGTTTCCGTGGAGACGCAAG TTGAGCCTTTGTAAATGGGCA 
Tnfa ACGGCATGGATCTCAAAGAC AGATAGCAAATCGGCTGACG 
Il1b AAATACCTGTGGCCTTGGGC CTTGGGATCCACACTCTCCAG 
Il6 AGTGAGGAACAAGCCAGAGC CATTTGTGGTTGGGTCAGG 
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Chapter 4 – Weight Regain in Formerly Obese Mice Hastens the Development of 
Hepatic Steatosis and Reveals Impaired Adipose Tissue Function 
Abstract 
Cycles of weight loss and regain are common in people attempting to lose excess 
adiposity. We sought to investigate the impact of weight regain in formerly obese mice 
on metabolic health, adipose tissue architecture, and stromal cell function. A diet-switch 
model was employed for obesity induction, weight loss, and weight regain in mice. 
Epididymal white adipose tissue of formerly obese mice failed to expand in response to 
repeat exposure to high-fat diet and retained elevated numbers of macrophages and T 
cells. Weight regain was associated with hyperinsulinemia and disproportionally elevated 
liver mass, hepatic triglyceride content, and serum transaminase concentrations. These 
effects occurred despite an extended six month weight loss cycle and demonstrate that 
formerly obese mice maintain durable alterations in their physiological response to 
weight regain. Epididymal adipose tissue of formerly obese mice secreted factor(s) that 
actively inhibited adipogenesis of 3T3-L1 preadipocytes suggesting a potential 
mechanism to explain failed epididymal adipose tissue expansion during weight regain. 
These data indicate that metabolic and physiologic abnormalities manifest in formerly 




Obesity is associated with increased risk for a number of co-morbidities including 
insulin resistance, type 2 diabetes, and cardiovascular disease. Weight loss, through 
caloric restriction or bariatric surgery, improves metabolic dysfunction and can reduce 
inflammation within adipose tissue (170-172). Unfortunately, long-term maintenance of 
even 10% weight loss is difficult, with only around 20% of people able to maintain this 
reduction beyond one year (191; 192). Even bariatric surgery, which can achieve 
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dramatic initial weight loss effects, has highly variable long-term weight management 
success with substantial variation in long-term weight loss outcomes (193; 194). One 
study found over 48% failure rate in long-term weight loss management after gastric 
banding procedures, with over 60% failure rates in patients originally lost to short-term 
follow-up (195). Weight regain, regardless of the method used for initial weight loss, is a 
common occurrence. 
An open question within the field is whether weight regain and weight cycling 
adversely alters metabolic health. The majority of recent research suggests that weight 
cycling is not associated with increased metabolic risk factors in humans when compared 
to those that remain overweight or obese (196-198). For example, analysis from the 
Action for Health in Diabetes (Look AHEAD) clinical trial found no negative 
associations between regaining weight versus having lost no weight at all when 
comparing HbA1c, blood pressure, HDL cholesterol, and blood triglycerides (199). 
However, few studies have evaluated metabolic parameters and altered physiological 
responses during the active weight regain cycle or examined the long-term effects on 
adipose tissue function and architecture. Rodent studies have found altered fatty acid 
metabolism and increased lipoprotein lipase, serum triglycerides, and serum cholesterol 
during high-fat diet (HFD) re-feeding beyond what was observed in rodents consistently 
fed HFD ad libitum (200-202). Weight cycling can also increase inflammatory markers 
within adipose tissue and has been associated with insulin resistance (175; 203). These 
findings suggest metabolic perturbations could exist that only clearly manifest during 
weight regain in formerly obese subjects. 
In support of this possibility, recent research suggests that weight loss is not 
capable of fully resolving life-long metabolic syndrome risk or reducing markers of 
adipose tissue dysfunction. Inflammatory gene expression within the adipose tissue of 
formerly obese human subjects remains high compared to lean subjects (126; 129). 
Results from mouse studies show similar persistent expression of inflammatory cytokines 
in adipose tissue despite weight loss including IL-6, IL-1β and TNFα (125; 130; 173; 
174; 204). It was recently demonstrated that weight loss incompletely resolved adipose 
tissue inflammation and insulin sensitivity in both mice and humans (125). Our group 
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recently reported that inflammatory CD11c
+
 macrophages are maintained within adipose 
tissue despite extended weight loss along with persistent impairment in insulin tolerance 
(204).  
In this study, we sought to identify metabolic and inflammatory perturbations 
associated with early weight gain in formerly obese mice compared with lean or obese 
mice. We found that the epididymal white adipose tissue (eWAT) of formerly obese mice 
had impaired expansion and reduced lipid storage capacity with HFD re-feeding. This 
effect persisted despite an extended six month period off HFD for the weight loss cycle. 
After weight regain, mouse eWAT was found to secrete factors that actively inhibited in 
vitro adipogenesis and lipid storage in 3T3-L1 cells. This failure for eWAT to expand 
was associated with increased hepatic triglyceride storage and elevated transaminase 
levels in serum after weight regain. We believe there may be certain unique metabolic 
abnormalities that develop at a hastened rate in formerly obese subjects during weight 
regain as a result of unresolved effects that persist despite weight loss. 
 
Materials and Methods 
Animals and Animal Care 
Male C57BL/6J mice were purchased from Jackson Laboratory. Six-week old 
male mice were fed control normal diet (ND; LabDiet PicoLab 5L0D 4.09 kcal/gm 
29.8% protein, 13.4% fat, 56.7% carbohydrate) or high-fat diet (HFD; Research Diets 
D12492, 5.24 kcal/gm 20% protein, 60% fat, 20% carbohydrate). 
Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed 
after 6 hours fasting. Mice were injected IP with D-glucose (0.7 g/kg) for GTTs and 
human recombinant insulin (1 U/kg) for ITTs. Glucose was measured using FreeStyle 
Lite blood glucose monitoring system. Insulin was measured by ELISA (Crystal Chem). 
Energy metabolism was measured using Comprehensive Lab Animal Monitoring System 
analysis (CLAMS, Columbus Instruments). All mouse procedures were approved by the 
University of Michigan Committee on Use and Care of Animals and were conducted in 
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compliance with the Institute of Laboratory Animal Research Guide for the Care and Use 
of Laboratory Animals. 
 
Gene expression analysis 
RNA was extracted from adipose using Trizol LS (Life Technologies) and cDNA 
generated using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
SYBR Green PCR Master Mix (Applied Biosystems) and the StepOnePlus System 
(Applied Biosystems) were used for real-time quantitative PCR. Gapdh expression was 
used as an internal control for data normalization. Samples were assayed in duplicate and 
relative expression was determined using 2
−ΔΔ
 CT method.  
Primers used in this study are listed in Table 7.  
 
Immunoblotting and Immunofluorescence 
Adipose tissue was homogenized in RIPA lysis buffer with phosphatase 
inhibitors. Protein concentration was determined using Bio-Rad Protein Assay Dye 
Reagent. Proteins were labeled and visualized using Odyssey infrared imaging system 
(Li-Cor Bioscience). Antibodies used for immunoblotting: PPARγ (81B8), IRS-1, 
Phospho-Akt (Ser473), AKT, Adiponectin (C45B10) (Cell Signaling Technology) and β-
Actin (AC-40) (Sigma-Aldrich).  
Whole-mount adipose tissue explantsfixed overnight in a 2% paraformaldehyde 
solution were used for immunofluorescence. Antibodies used for immunofluorescence: 
caveolin (BD Pharmingen) and Mac2 (Galectin-3) (eBioM3/38) (eBioscience). 
 
Isolation of Adipose Tissue Stromal Vascular Fraction and Flow Cytometry  
Excised adipose tissue was digested in RPMI with 0.5% BSA and 1 mg/ml type II 
collagenase for 25 min at 37°C and the stromal vascular fraction (SVF) was separated 
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from adipocytes by centrifugation. The following antibodies were used for flow 
cytometry: CD45 (30-F11), CD3e (145-2C11), CD4 (GK1.5), CD8a (53-6.7), CD11c 
(N418), Sca-1 (Ly-6A/E) (D7), CD31 (390) (eBioscience), PDGFRα (RM0004-3G28) 
(Abcam), and CD64 (X54-5/7.1) (BD Pharmingen). Analysis was performed using a BD 
Biosciences FACSCanto II and FlowJo v.10 (Treestar). 
 
Explant Conditioned Media  
200mg epididymal adipose tissue explants were cultured in serum-free AIM V 
media with AlbuMax and BSA (Life Technologies) to create conditioned media (CM). 
For CM treatment, confluent 3T3-L1 cells were treated with a 1:1 mixture of CM and 
MDI differentiation media (final concentration 0.5mM methylisobutylxanthine, 1μM 
dexamethasone and 10μg/mL human recombinant insulin in DMEM); after 3 days media 
was replaced with another 1:1 mixture of CM and insulin medium (10μg insulin in 
DMEM). For cytokine and chemokine treatments 3T3-L1 cells were treated during both 
phases of differentiation. For TNFα neutralizing experiments CM was treated 1 hour with 
100 ng/mL blocking antibody before using the CM in 3T3-L1 differentiation cultures at a 
final concentration of 50ng/mL (D2H4 mAb, CST). Chemokine treatments were 
performed at 10ng/mL (PeproTech).  
Mouse Cytokine Antibody Array (R&D Systems) was used to evaluate cytokine 
output from adipose tissue explants after 48 hours conditioning and samples were pooled 
from 3 mice. Quantitation by ImageJ after background subtraction and normalization to 
reference controls. 
 
Liver Triglyceride Quantification 
Approximately 100mg frozen liver samples were homogenized in 300μL lysis 
buffer (10% NP-40, 50mM Tris-HCl pH 7.5 and 100mM NaCl) and 200μL chloroform 
was added before drying in a vacuum concentrator. Lipids were extracted using 400μL 
chloroform and transferred to new tubes for drying. Lipids were reconstituted with 1mL 
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per 100mg tissue of a butanol mixture (6% butanol, 3.33% Triton-X100 and 0.66% 
Methanol) and quantified using the Infinity
™




All values are reported as mean ± SEM unless otherwise noted. Statistical 
significance of differences were determined using unpaired two-tailed Student’s t-test or 
one-way ANOVA for multiple groups using Fisher’s least significant difference test for 
planned statistical comparisons. All relative gene expression data was compared using 
two-way ANOVA with Dunnett’s multiple comparisons correction. All analysis was 
performed using GraphPad Prism V6.05. 
 
Results 
High-fat diet re-challenged mice have greater than anticipated increases in body weight 
but reduced eWAT mass 
Weight loss was modeled based on the withdrawal of high-fat diet (HFD) from 
diet-induced obese mice (204). Male C57BL/6J mice were fed HFD (60% kcal fat) or ND 
(13.5% kcal fat) for 12 weeks. Obese mice were then maintained on HFD or switched to 
ND for 8 weeks to induce weight loss. After weight loss, mice were then re-challenged 
with HFD for 6 weeks (RC HFD). Age-matched control mice included: a) a group 
continuously fed HFD long-term for all 26 weeks (LT HFD); and b) mice fed ND for the 
first 20 weeks followed thereafter by short-term HFD challenge for the final 6 weeks (ST 
HFD) (Figure 4-1A).  
After weight loss, body weight was 32.1g (SD ± 1.45) and was similar to age-
matched ND mice 30.35g (SD ± 1.11) (Figure 4-1B). After HFD re-challenge the body 
weight of RC HFD mice was significantly elevated (52.68g SD ± 1.52) compared to ST 
HFD mice (43.85 SD ± 5.21), but RC HFD mice were not significantly different from LT 
HFD mice (52.0 SD ± 4.0) (Figure 4-1C). Energy metabolism analysis of mice after 
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weight loss showed a small, but significant, reduction in total energy expenditure in 
weight loss mice compared to ND mice which was further reduced in mice fed HFD for 
20 weeks (Figure 4-1D). One week after initiating HFD re-challenge, RC HFD mice had 
higher food intake than ST HFD and LT HFD mice (Figure 4-1E). The reduced energy 
expenditure and increased HFD intake likely explains the significantly elevated body 
weight of RC HFD mice compared to ST HFD mice.  
GTTs and ITTs were performed during HFD re-challenge to assess metabolic 
differences between ST HFD and RC HFD mice. GTTs were similar between RC HFD 
and ST HFD mice after 2 weeks and 4 weeks of HFD (Figure 4-1F-G). Fasted blood 
glucose and serum insulin were also measured after 6 weeks of HFD re-challenge. RC 
HFD mice had a trend towards reduced fasting blood glucose levels compared to ST HFD 
mice, but this did not reach significance (Figure 4-1H). Serum insulin levels were 
significantly increased in RC HFD mice and similar to levels measured in LT HFD mice 
(Figure 4-1I). ITTs revealed comparable insulin sensitivity between ST HFD and RC 
HFD mice and impaired insulin tolerance in LT HFD mice (Figure 4-1J). 
Despite increased body weights, the epididymal white adipose tissue (eWAT) in 
RC HFD mice was paradoxically smaller than ST HFD mice and made up a smaller 
percentage of total body weight (Figure 4-1K-L). The eWAT adipocyte size distribution 
from both ST HFD and RC HFD mice were not different (Figure 4-1M). These curves 
were similar to LT HFD (not shown), and the average adipocyte size in ST HFD, RC 
HFD and LT HFD were not significantly different from each other (Figure 4-1M). 
Overall, the data suggest reduced eWAT mass was not due to a deficiency in individual 





Figure 4-1 – Weight loss and HFD re-challenge model. (A) Cartoon showing obesity 
induction, weight loss and HFD re-challenge model. Body weights after (B) weight loss and (C) 
HFD re-challenge. (D) Energy expenditure after weight loss and (E) food intake one week after 
starting HFD re-challenge phase. (F-G) Glucose tolerance testing at 2 and 4 weeks of HFD re-
challenge. (H) Fasted blood glucose, (I) fasted serum insulin and (J) insulin tolerance after 6 
weeks of HFD re-challenge. (K) Total epididymal WAT (eWAT) weight and (L) eWAT as a 
percent of total body weight with (M) eWAT adipocyte size distribution. 
*
p < 0.05, 
**
p < 0.01, 
****
p <0.0001; significance was only compared for ST HFD versus RC HFD, LT HFD versus RC 




eWAT of formerly obese mice had deranged protein and gene expression profiles after 
HFD re-challenge 
To better understand why the eWAT depots of RC HFD were resistant to 
expansion after HFD re-challenge we examined adipose tissue histology of all groups. 
We previously reported that the eWAT of formerly obese mice retain many features 
associated with chronic obesity including increased fibrosis, continual crown-like 
structure (CLS) development, and maintenance of pro-inflammatory leukocytes despite 
weight loss (204). As anticipated, histology and immunofluorescence of RC HFD and LT 
HFD eWAT revealed substantial CLS presence and leukocyte infiltration while ST HFD 
mice had minimal identifiable CLS (Figure 4-2A). Adipocytes are critically dependent on 
expression of key genes encoding proteins for insulin signaling (Insr, Irs1, Akt, and 
Glut4) as well as transcription factors important for adipogenesis and mature adipocyte 
function (Cebpa and Pparg) (205). Immunoblots of eWAT revealed reductions in 
proteins associated with mature differentiated adipocytes including PPARγ, IRS-1, and 
AKT in RC HFD and LT HFD mice compared to ST HFD mice (Figure 4-2B-C). Gene 
expression analysis showed reduced expression of InsrI, Irs1, Cebpa, Pref1 and Glut4 in 
ST HFD, LT HFD, and RC HFD eWAT compared to ND mice. RC HFD and LT HFD 
gene expression was further reduced compared to ST HFD for these same genes with 




Figure 4-2 – HFD re-challenge increases epididymal adipose tissue crown-like structures 
and reduces expression of proteins essential for mature adipocyte development and 
function. (A) Immunofluorescence and H&E stained eWAT slides representative for each diet 
condition showing CLS development and maintenance. (B) Representative immunoblots from 
eWAT showing select adipocyte maturation and insulin signaling proteins. (C) Quantification of 
densitometry measurements from immunoblots of whole eWAT. (D) Expression of select 
adipocyte maturation genes from eWAT. Two-way ANOVA with Dunnett’s multiple 
comparisons for D. 
*
p < 0.05, 
**
p < 0.01, 
****
p <0.0001, significance was only compared for ST 





Figure 4-3 – Inguinal adipose tissue shows resistance to derangement with HFD re-
challenge. Inguinal WAT (iWAT) (A) weight, (B) iWAT as percent of total body weight and (C) 
ratio of iWAT to eWAT after HFD re-challenge. (D) H&E stained iWAT slides representative for 
each diet condition showing limited crown-like structures. (E) Expression of select adipocyte 
maturation genes from whole iWAT. (F) Expression of select inflammatory cytokine genes from 
whole iWAT. 
*
p < 0.05, 
**
p < 0.01, 
****
p <0.0001, significance was only compared for ST HFD 
versus RC HFD, LT HFD versus RC HFD or ND versus WL. 
 
Inguinal subcutaneous adipose tissue has increased mass after HFD re-challenge but is 
protected from the deranged features found in eWAT 
To identify depot specific effects of weight regain, we evaluated subcutaneous 
inguinal WAT (iWAT) architecture and gene expression. Total iWAT weight was 
increased in RC HFD mice, compared to ST HFD, and was similar to LT HFD. However, 
as a percent of total body weight, iWAT was not significantly different between HFD 
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groups (Figure 4-3A-B). When iWAT weight was compared to eWAT weight, ST HFD 
had similar ratios to what was observed in ND and WL mice. In contrast, RC HFD and 
LT HFD had significantly greater iWAT to eWAT ratios (Figure 4-3C), suggesting a 
different pattern of adipose tissue depot lipid storage. Histology revealed no substantial 
differences in tissue structure or CLS development between diet groups in iWAT (Figure 
4-3D). Gene expression from iWAT revealed HFD induced reductions in most mature 
adipocyte genes compared to ND control, but no significant differences between ST 
HFD, RC HFD and LT HFD groups were observed except for Lpl which was increased in 
ST HFD iWAT (Figure 4-3E). Inflammatory cytokine gene expression was also 
evaluated in iWAT revealing no significant differences between ST HFD, RC HFD and 
LT HFD mice (Figure 4-3F). Overall, in contrast to eWAT, iWAT expansion in RC HFD 
mice was not significantly impaired compared to ST HFD mice and was associated with a 
lack of CLS development. 
 
HFD re-challenge increased hepatic steatosis and serum markers of liver dysfunction  
Liver histology from ND and WL mice was similar showing resolution of hepatic 
steatosis after 8 weeks off of HFD (Figure 4A). By histology, RC HFD mice had 
significantly elevated hepatic lipid involvement compared to ST HFD and similar to LT 
HFD mice (Figure 4-4A-B). Liver weights were significantly elevated in RC HFD mice 
compared to ST HFD mice both in absolute and relative liver mass (Figure 4-4C-D). As a 
result, total hepatic triglyceride content was more than 2 fold higher in RC HFD and LT 
HFD mice when compared to ST HFD (Figure 4-4E-F). Serum triglyceride 
concentrations were similar between ST HFD, RC HFD, and LT HFD mice (Figure 4-
4G). Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels 
were quantified as markers of liver stress and damage. RC HFD mice had significantly 
elevated levels of both markers with more than two-fold higher serum ALT 
concentrations than ST HFD mice (Figure 4-4H). Overall, these results show that despite 
the same duration of HFD exposure as ST HFD mice, RC HFD mice have significantly 




Figure 4-4 – Increased liver steatosis and signs of liver damage with HFD re-challenge. (A) 
Representative H&E stained slides from livers showing steatosis development and (B) percent of 
surface area with lipid involvement from H&E images. (C) Liver weight and (D) liver as a 
percent of total body weight. (E) Liver triglyceride concentration and (F) total liver triglyceride 
content. Serum concentrations for (G) triglyceride, (H) aspartate aminotransferase (AST, left) and 
alanine aminotransferase (ALT, right). 
*
p < 0.05, 
**
p < 0.01, 
****
p <0.0001, significance was only 





Figure 4-5 – Liver lipid metabolism and lipogenesis gene expression is not significantly 
different between ST HFD and RC HFD mice groups. Gene expression for select liver (A) 
lipid metabolism, (B) glucose metabolism, (C) inflammatory cytokine genes, and (D) leukocyte 
genes. 
*
p < 0.05, 
***
p < 0.001, 
****
p <0.0001, significance was only compared for ST HFD versus 
RC HFD, LT HFD versus RC HFD or ND versus WL. 
 
To determine if the increased hepatic triglyceride content was due to increased 
liver lipogenesis, we evaluated a number of hepatic lipid and glucose metabolism genes. 
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Compared to ST HFD and RC HFD mice, LT HFD induced Lpl and Pparg expression 
but showed no significant differences in expression of Scd1, Srebp1, Fasn, Me1, Acaca, 
Fabp1, G6pc, Pck1, or Gck. No differences were observed in the expression of genes 
involved in lipid metabolism between RC HFD and ST HFD liver samples (Figure 4-5A-
B). Liver inflammatory gene expression did reveal significantly increased expression of 
Tnfa in RC HFD and LT HFD mice, but no differences in Il1b and Il6 expression was 
observed (Figure 4-5C). Leukocyte gene expression for F480 and Cd3 was elevated in 
LT HFD mice but was not significantly different between ST HFD and RC HFD mice 
(Figure 4-5D). These results suggest that the increased hepatic triglyceride storage was 
not the result of increased de novo lipogenesis in liver.  
 
The effects observed with HFD re-challenge are retained despite extended time removed 
from HFD for the weight loss cycle 
To evaluate the durability of the effects of prior obesity, we extended the weight 
loss cycle to 24 weeks and then re-challenged mice with HFD for 6 weeks (Ex-RC HFD) 
(Figure 4-6A). Age-matched mice were maintained on extended ND (Ex-ST HFD) and 
extended HFD (Ex-LT HFD) were used for controls. After HFD, the Ex-RC HFD group 
weighed significantly more than age-matched Ex-ST HFD mice and significantly less 
than Ex-LT HFD mice (Figure 4-6B). EWAT was reduced in Ex-RC HFD and Ex-LT 
HFD mice compared to Ex-ST HFD mice in both total mass and as a percent of body 
weight (Figure 4-6C-D). EWAT immunofluorescence revealed increased CLS in Ex-RC 
HFD and Ex-LT HFD mice compared to Ex-ST HFD mice (Figure 4-6E). Gene 
expression of eWAT revealed no significant differences between diet conditions for 
evaluated adipocyte maturation genes (Figure 4-6F). IWAT weight was not significantly 
different between Ex-RC HFD and Ex-ST HFD mice but both were less than Ex-LT HFD 
(Figure 4-6G-H). Fasting blood glucose of Ex-RC HFD mice was significantly elevated 




Liver histology revealed substantial lipid involvement with all three diet conditions 
(Figure 4-7A). Total liver weight, and liver weight as a percent of body weight, was 
significantly elevated in Ex-RC HFD and Ex-LT HFD mice compared to Ex-ST HFD 
(Figure 4-7B-C). Liver triglycerides were increased in the Ex-RC HFD and Ex-LT HFD 
mice compared to Ex-ST HFD mice (Figure 4-7D-E). Liver gene expression revealed no 
significant differences between groups for lipid and glucose metabolism genes assessed 
(Figure 4-7F-G). Overall the results show that increasing the ND-switch time from 8 
weeks to 24 weeks did not improve eWAT lipid storage capability nor reduce liver 
steatosis development with HFD re-challenge.  
 
Epididymal adipose tissue leukocyte content is increased after HFD re-challenge 
Flow cytometry revealed increased total leukocyte accumulation in the eWAT 
stromal vascular fraction (SVF) of RC HFD compared to ST HFD but less than what was 
observed in LT HFD mice (Figure 4-8A). The total number of eWAT adipose tissue 
macrophages (ATM) was also significantly increased in RC HFD mice as well as the 
frequency of CD11c
+
 ATM (Figure 4-8B-C). Analysis of adipose tissue T cell 
populations showed a non-significant increase of total T cell content in RC HFD mice. 
However, there was a significantly higher frequency of CD8
+
 T cells in RC HFD mice 
compared to ST HFD mice (Figure 4-8D-F). EWAT inflammatory cytokine gene 
expression showed Tnfα was increased in RC HFD and LT HFD mice compared to ST 
HFD, but Il1β and Il6 expression did not differ between groups (Figure 4-8G). Overall, 
the results suggest that HFD re-challenge promotes increased inflammation and 





Figure 4-6 – HFD re-challenge after 24 weeks weight loss cycle reveals similar defects in 
eWAT expansion capacity. (A) Cartoon showing extended ND-switch period of 24 weeks 
followed by 6 weeks of HFD re-challenge. (B) Body weight of mice after 24wk ND-switch and 
then re-challenging with HFD. (C) eWAT weight and (D) eWAT as a percent of total body 
weight after HFD re-challenge. (E) Representative immunofluorescence images showing CLS 
retention. (F) Expression of select adipocyte maturation genes from whole eWAT. (G) iWAT 
weight and (H) iWAT as a percent of total body weight. (I) Fasting blood glucose after HFD 
challenge. 
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001, significance was only compared for Ex-ST HFD 




Figure 4-7 – Increased liver triglycerides and steatosis after HFD re-challenge of extended 
weight loss cycle mice. (A) Representative liver H&E slides showing steatosis development. (B) 
Liver weight and (C) liver as a percent of total body weight. (D) Liver triglyceride concentration 
and (E) total liver triglyceride content after HFD re-challenge. Gene expression for select liver 
(F) lipid metabolism and (G) glucose metabolism genes. 
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001, 
****
p 
<0.0001, significance was only compared for Ex-ST HFD versus Ex-RC HFD, Ex-LT HFD 





Figure 4-8 – Increased CD11c
+ 
ATM accumulation and inflammation with HFD re-
challenge. (A) Frequency of CD45
+
 leukocytes of all eWAT SVF. (B) Total ATM content per 




 ATM that express CD11c. (D) Total T cell 
content per eWAT pad. Frequency of (E) CD4
+
 and (F) CD8
+ 
cells of all adipose tissue T cells. 
(G) Expression of select inflammatory cytokine genes from whole eWAT.  
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001, significance was only compared for ST HFD versus RC HFD, LT HFD versus RC 













 preadipocytes as (A) a frequency of all SVF cells and (B) total 
preadipocytes per eWAT pad. (C) Frequency of preadipocytes in iWAT SVF and (D) total 
preadipocytes per iWAT pad. 
*
p < 0.05, 
***
p < 0.001, significance was only compared for ND 




Figure 4-10 – Conditioned media from eWAT explants of formerly obese mice inhibits 
adipocyte differentiation and reduces lipogenesis. Gene expression for (A) adipocyte 
maturation genes and (B) collagen genes after differentiation induction in the presence of eWAT 
explant conditioned media from the respective diet conditions. Oil red O staining of lipid droplets 
within differentiated adipocytes shown as (C) representative micrographs and (D) relative total 
extracted oil red O content from wells. (E) eWAT explant multiplex cytokine array (n = 2 per diet 
condition). (F) Extracted relative oil red O content from differentiated 3T3-L1 cells after 
102 
 
treatment with (left) 10ng/mL of individual chemokines identified from multiplex cytokine array 
or (right) simultaneous treatment with all identified chemokines at 10ng/mL each (Significance 
compares to Differentiated Control). (G) Extracted relative oil red O absorbance after treatment 
with CM from ST HFD, RC HFD or LT HFD with or without the addition of 50ng/mL 
neutralizing anti-TNFα antibody (αTNF) during differentiation. Undiff. = Undifferentiated 
Control; Diff. = Differentiated Control; All Chemok. = All identified chemokines. 
*









Obesity imposes a durable increase in eWAT preadipocyte content despite weight loss 
Our observations of decreased eWAT expansion in RC HFD mice, despite similar 
adipocyte size as ST HFD mice, suggested that adipogenesis may be impaired in formerly 








 cells from the SVF (206; 207). The eWAT tissue of WL and 
20wk HFD mice had elevated preadipocyte content, both as a frequency of SVF and in 
total number, when compared to ND mice (Figure 4-9A-B). 20wk HFD mice also had 
elevated preadipocytes in iWAT, but ND and WL iWAT had similar numbers of 
preadipocytes (Figure 4-9C-D). The data show that the eWAT of formerly obese mice 
maintains more preadipocytes and suggests obesity imposes a durable change to eWAT 
adipogenic potential despite weight loss.  
 
EWAT of formerly obese mice secretes factors that directly inhibit adipogenesis 
We utilized an in vitro model of adipogenesis using the 3T3-L1 preadipocyte cell 
line to examine if eWAT from formerly obese mice secreted factors that blocked 
adipogenesis. Conditioned media (CM) was collected from eWAT explant cultures in 
serum-free media for 24 hours. CM from formerly obese mice (WL CM) significantly 
increased genes normally associated with preadipocyte cells, rather than mature 
adipocytes, including Pref1, Col1a1, Col3a1, Acta2 and Fn1 expression compared to ND 
CM treatment (Figure 4-10A-B). Oil red O was used on differentiated 3T3-L1 cells to 
determine lipid storage capacity and adipogenesis. WL and HFD CM treatment 
significantly reduced lipid storage compared to ND CM treatment which was similar to 
control untreated differentiated cells (Figure 4-10C-D).  
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To determine what factors might be responsible for inhibiting adipogenesis, we 
used a cytokine array to evaluate cytokine concentrations in eWAT CM after 48 hours 
culture. Several cytokines were either not significantly different between diet conditions 
or were not detectable. However, we observed that IL1ra and chemokines CCL4, 
CXCL9, CCL5 and CCL12 were elevated in WL CM compared to ND CM (Figure 4-
10E). Treatment of 3T3-L1 cells during differentiation with these chemokines revealed a 
small, but significant, reduction in differentiation efficiency (Figure 4-9F). However, 
treatment with any one chemokine failed to inhibit differentiation to the same degree as 
WL or HFD CM, and treatment with all four simultaneously abolished the inhibitory 
effect. 
TNFα is a potent inhibitor of adipogenesis (208). Gene expression for Tnfα was 
found to be slightly elevated in WL eWAT and substantially elevated in RC HFD and LT 
HFD eWAT (Figure 4-8G). To determine if TNFα might be playing a significant role 
inhibiting adipogenesis in our culture model, we added a TNFα neutralizing antibody to 
the CM before treating 3T3-L1 cells. Treatment of differentiating 3T3-L1 cells with ST 
HFD, RC HFD or LT HFD CM resulted in equivalent inhibition of differentiation and 
was similar to what was observed after WL CM or HFD CM treatment (Figure 4-10G). 
Exposure to TNFα neutralizing antibody caused slight, but not significant, improvements 
in differentiation efficiency indicating TNFα plays, at best, a minor role for inhibiting 
adipogenesis in our CM culture system. Overall, the results show that the eWAT of obese 




We’ve previously published that the eWAT of formerly obese mice maintains 
increased numbers of activated leukocytes along with persistent abnormalities in eWAT 
structure and adipogenic protein expression (204). In this study, we extend our 
observations to assess the metabolic and inflammatory consequences of re-challenging 
formerly obese mice with HFD. We hypothesized that basic functions of adipose tissue, 
such as lipid storage, may be permanently impaired in formerly obese mice and explored 
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this with a dietary manipulation model of obesity, weight loss, and weight regain in mice. 
This animal model was designed to mimic weight regain trends often observed in people 
after interventions of caloric restriction such as reduced calorie meal replacement for 
weight loss. Our major finding was that eWAT of formerly obese mice was not capable 
of properly storing excessive nutrients and, as a result, led to increased ectopic lipid 
storage in organs such as liver and iWAT. This functional derangement persists despite 
extended time off of HFD and suggests a prolonged, possibly permanent, impact of 
obesity on eWAT function and architecture. The permanent changes in eWAT in the RC 
HFD groups included increased: a) ATM accumulation; b) increased CD8+ T cell 
accumulation; c) increased inflammatory cytokine expression; and d) increased numbers 
of collagen+ preadipocytes. Furthermore, secreted factors produced from eWAT of 
formerly obese mice inhibited an in vitro model of adipogenesis and may be responsible 
for limiting the lipid storage capacity of eWAT in vivo. 
Consistent with our hypothesis, HFD challenge of formerly obese mice led to 
reduced eWAT expansion compared to a similar duration of HFD challenge of weight-
matched lean mice. Importantly, the identical adipocyte sizing curves suggest that the 
reduced eWAT expansion is not due to less lipid uptake per adipocyte. Our data suggest 
there are fewer functionally mature adipocytes present in formerly obese eWAT which 
limits the overall lipid storage capacity of the entire fat pad. In support of this 
interpretation, we found that expression of several critical mature adipocyte-specific 
genes and proteins was significantly decreased in formerly obese eWAT and remained 
lower after HFD re-challenge. Interestingly, the iWAT tissue of formerly obese mice was 
capable of expanding to HFD re-challenge proportional to body weight increases. The 
gene expression profile of iWAT showed some improvements compared to eWAT for 
several genes including Lpl, Pparg, and Glut4. However, this may not sufficiently 
explain the functional differences observed between these depots in our model. Future 
research is required to help identify why mouse iWAT tissue responds so differently from 
eWAT tissue during HFD re-challenge. 
Examination of livers from RC HFD mice revealed disproportionally increased 
liver mass, relative to ST HFD mice, with substantially increased lipid involvement and 
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total triglyceride content. Increased hepatic steatosis was associated with increased serum 
concentrations of AST and ALT indicating liver damage or abnormal liver function. The 
ALT to AST ratio was greater than 2:1 in both RC HFD and LT HFD mice, compared to 
1.3:1 in ST HFD mice. This ratio matches a classical change observed in patients with 
early stage non-alcoholic fatty liver disease (NAFLD) and is typically associated with 
obesity and increased risk of type 2 diabetes development (209-211). In our model, ST 
HFD and RC HFD mice had similar fasting glucose measures, glucose response curves, 
and insulin response curves despite the substantially increased triglyceride load found in 
their livers. However, fasting insulin levels were almost two-fold higher in RC HFD and 
LT HFD mice indicating increased insulin resistance in the RC HFD mice. Our results 
are in agreement with previous findings showing accrued liver steatosis and impaired 
liver insulin signaling responsiveness in murine weight cycling models (175; 212).  
Increased liver steatosis can occur as a result of four broad possible mechanisms 
including reduced liver fatty acid oxidation, reduced triglyceride export, increased 
hepatic lipogenesis, and increased lipid uptake from the serum (213). In normal 
conditions, hepatic de novo lipogenesis is a relatively minor contributor to liver 
triglyceride content but in NAFLD this can increase due to an induction of genes critical 
for de novo lipogenesis (214-217). Several of these genes were evaluated and revealed no 
differences between ST HFD and RC HFD mice suggesting the increased steatosis was 
not due to amplified hepatic fatty acid synthesis. Liver fatty acid oxidation rates and 
triglyceride export have been found to not change, or even increase, with NAFLD and 
obesity (218-222). As a result, these pathways would not be expected to play significant 
roles in mediating the increased liver steatosis observed with our model. Based on the 
reduced lipid storage capacity of eWAT we believe the most likely explanation for 
increased liver steatosis in RC HFD mice is increased lipid shunting to, and uptake by, 
the liver. However, we can’t rule out the possibility that one of these other mechanisms 
may be partly responsible. This merits more detailed investigation in future studies 
including the use of isotope-labeled tracers to identify the sources contributing to hepatic 
triglycerides during HFD re-challenge.  
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We extended the time mice were off HFD during the weight loss cycle to 
determine how permanent the effects of obesity were. After 24 weeks of HFD removal 
the eWAT tissue still failed to expand appropriately with HFD re-challenge. Examination 
of liver revealed the same disproportionate increase in liver mass and increased total 
hepatic triglyceride content. The results show the impact of diet-induced obesity on 
eWAT function does not resolve despite prolonged time off HFD. 
The limited capacity for eWAT expansion was observed despite a quantitative 
increase in preadipocytes in formerly obese mice, suggesting that they may have 
impaired capacity for adipogenic differentiation. Consistent with this, we observe that 
WL CM and HFD CM inhibited 3T3-L1 adipogenic potential. Treatment of 3T3-L1 cells 
with individual chemokines suggested only moderate inhibition of adipogenesis. 
Treatment with all four identified chemokines, however, abolished the inhibitory effect 
and suggests limited potential for inhibiting adipogenesis in vivo. Treatment with an anti-
TNFα neutralizing antibody also showed no differentiation improvement and confirmed 
that TNFα may play little, if any, role towards inhibiting adipogenesis in our culture 
system. Given the evidence available we investigated the most likely anti-adipogenic 
candidates. However, several other adipogenesis inhibitors exist that have yet to be 
examined in our system including, but not limited to, IL-6 (223), Wnt-5a (224), IL-1β 
(225; 226), macrophage inhibitory factor homolog d-dopachrome tautomerase (227), and 
even fatty acids like arachidonic acid (228). It’s also important to note another possible 
explanation for limited eWAT expansion in vivo wherein preadipocytes may be 
intrinsically altered by obesity and are no longer as capable of maturing into lipid-storing 
adipocytes. As a result, the adipocyte precursors in vivo may not be capable of properly 
responding to increased lipid storage demands even if the secreted factor could be found 
and nullified. Future work will continue to explore the relative importance of direct 
exposure to adipogenesis inhibitors versus permanent defects in adipocyte maturation 
remaining after obesity. 
ST HFD eWAT CM also inhibited in vitro adipogenesis indicating that even a 
short 6 week interval of HFD was sufficient to promote expression and/or secretion of the 
factor. Interestingly, the eWAT of ST HFD mice had expanded to near the maximum size 
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limits we tend to observe for eWAT tissue expansion before the depots begin to shrink 
(approximately 3g), which is a phenomenon observed by others as well (56). Expression 
of the factor(s) may correlate with the natural transition point for eWAT when the depot 
switches from an expansion phase to contraction. An interesting model to compare our 
study with is the adiponectin-overexpressing ob/ob mouse model which allows expansion 
of adipose tissue beyond normal limits observed in leptin deficient mice. These mice can 
grow to over 100g total body weight but are protected from many of the deleterious 
effects of diet-induced obesity including metabolic syndrome and liver steatosis (229). 
This suggests that limited expansion capacity of adipose tissue is central to ectopic lipid 
deposition and hepatic steatosis development. In agreement with this, lipodystrophy, 
having at least partial absence of adipose tissue, is associated with NAFLD and indicates 
a fundamental importance for adipose tissue expansion in preventing liver steatosis (230; 
231).  
Taken together, we were able to identify unique physiologic differences 
associated with weight regain in formerly obese mice. Our observations are part of a 
growing body of literature showing that features normally associated with obese adipose 
tissue, including inflammation and insulin resistance, are maintained despite weight loss 
in both mice and humans (125; 126; 129; 130; 173; 174). The results suggest that 
unresolved effects of obesity encourage the hastened emergence of severe metabolic 
abnormalities during weight regain including hepatic steatosis and insulin resistance. 
These findings indicate that weight gain may result in specific health consequences that 
are dependent on the subject’s entire weight history. Future work will continue to 
investigate the physiologic consequences of obesity that remain despite weight loss as 






Table 7 – Sequences for RT-PCR primers used in this chapter 
Gene Forward Reverse 
Insr TTTGTCATGGATGGAGGCTA CCTCATCTTGGGGTTGAACT 
Irs1 CGATGGCTTCTCAGACGTG CAGCCCGCTTGTTGATGTTG 




Lpl TGTGTCTTCAGGGGTCCTTAG GGGAGTTTGGCTCCAGAGTTT 
Pparg GGAAGACCACTCGCATTCCTT TCGCACTTTGGTATTCTTGGAG 
Akt1 ATGAACGACGTAGCCATTGTG TTGTAGCCAATAAAGGTGCCAT 
Glut4 GTGACTGGAACACTGGTCCTA CCAGCCACGTTGCATTGTAG 
Tnfa ACGGCATGGATCTCAAAGAC AGATAGCAAATCGGCTGACG 
Il1b AAATACCTGTGGCCTTGGGC CTTGGGATCCACACTCTCCAG 
Il6 AGTGAGGAACAAGCCAGAGC CATTTGTGGTTGGGTCAGG 
Scd1 GCTGGAGTACGTCTGGAGGAA TCCCGAAGAGGCAGGTGTAG 
Srebp1 GATGTGCGAACTGGACACAG CATAGGGGGCGTCAAACAG 
Fasn GGAGGTGGTGATAGCCGGTAT TGGGTAATCCATAGAGCCCAG 
Me1 GTCGTGCATCTCTCACAGAAG TGAGGGCAGTTGGTTTTATCTTT 
Acaca TAATGGGCTGCTTCTGTGACTC CTCAATATCGCCATCAGTCTTG 
Fabp1 ATGAACTTCTCCGGCAAGTACC CTGACACCCCCTTGATGTCC 
G6pc CGACTCGCTATCTCCAAGTGA GTTGAACCAGTCTCCGACCA 
Pck1 CTGCATAACGGTCTGGACTTC CAGCAACTGCCCGTACTCC 
Gck ATGGCTGTGGATACTACAAGGA TTCAGGCCACGGTCCATCT 
Fabp4 AAGGTGAAGAGCATCATAACCCT TCACGCCTTTCATAACACATTCC 
Col1a1 GTGCTCCTGGTATTGCTGGT GGCTCCTCGTTTTCCTTCTT 
Col3a1 CTGTAACATGGAAACTGGGGAAA CCATAGCTGAACTGAAAACCACC 
Col4a1 GCCAAGTGTGCATGAGAAGA AGCGGGGTGTGTTAGTTACG 
Acta2 CCAGGCATTGCTGACAGGAT CCACCGATCCAGACAGAGTAC 






Chapter 5 – Conclusions and Future Directions 
 
Summary 
This dissertation investigated and addressed several unresolved issues regarding 
metabolic and inflammatory changes that occur during obesity, weight loss, and weight 
regain. We first identified a better marker for delineating ATMs from other adipose tissue 
myeloid populations in mice and humans which has been a major technical limitation 
within the field. We show that obesity imparts a lasting impact on adipose tissue health 
and function that persists despite weight loss. As a result, weight regain in formerly obese 
mice was accompanied by hastened development of metabolic abnormalities including 
hyperinsulinemia, adipose tissue functional derangement, hepatic steatosis, and hepatic 
damage. The following discussion will outline the specific contributions for each data 
chapter, potential future directions, and major implications for these studies.  
 
Objectives, Major Findings, and Implications for Chapter 2 
In chapter 2, our objective was to test CD64 as a macrophage-specific marker for 
better discrimination of ATMs from other adipose-resident myeloid populations. We 
provide evidence supporting CD64 as a better marker than F4/80 for specific 
identification of ATMs from other myeloid cell populations that can express F4/80 
including ATDCs, eosinophils, and neutrophils. The inability to isolate ATMs from these 
other myeloid populations, without the use of several additional markers, has impaired 
our ability to properly attribute immune functions to the correct cell population. We 







 “macrophage-specific” pool which suggests that some previous 
studies utilizing this identification scheme may need to be revisited to clarify the 
respective functions of ATMs from other F4/80-expressing leukocytes.  
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An important result of this work is the definitive identifications of ATDCs as 
independent contributors to obesity-induced inflammation within adipose tissue. 
Historically, ATMs have been well studied and are believed to be essential direct 
contributors to the development of adipose tissue inflammation. Previous work from the 
Lumeng lab has also found that ATMs function as antigen-presenting cells in situ during 
obesity, indicating another mechanism by which ATMs may influence adipose tissue 
inflammation (144). However, we don’t have a clear understanding of the potential role 
ATDCs play in inflammation development, antigen presentation, or metabolic health. 
This chapter identified specific gene signatures associated with ATMs (high lysosomal 
and lipid storage, inflammatory cytokines, and complement) versus ATDCs (low 
inflammatory cytokine expression and high antigen processing and presentation). Both 
ATMs and ATDCs highly express MHC-II and T cell co-stimulatory markers and both 
were effective APCs ex vivo. So while ATMs and ATDCs may be functional APCs in 
vivo, they could also have unique additional functions which can now be better 
investigated through use of CD64. Finally, we show that CD64 can be useful as a marker 
for identification of human ATMs as well.  
Ongoing work continues to utilize this marker to better differentiate the respective 
functions of ATMs and ATDCs in different adipose tissue depots of both mice and 
humans. Use of this marker by researchers in the field will help reduce the number of 
markers necessary to delineate adipose-resident myeloid populations. As a result, it 
should help reduce the risk of flow cytometry results being confounded by contamination 
of other leukocyte populations when studying adipose tissue immune dynamics.  
 
Objectives, Major Findings, and Implications for Chapter 3 
In chapter 3, our objective was to perform a detailed investigation into the effects 
of weight loss on inflammatory leukocyte activation and composition within adipose 
tissue. Understanding leukocyte activation dynamics during weight loss helps inform our 
understanding of how adipose tissue inflammation continues to persist. We discovered 
that features normally associated with chronically-obese adipose tissue fail to resolve 
even with extended time removed from HFD. These results build onto recent findings 
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showing that adipose tissue inflammation can persist in rodents and humans after weight 
loss (125; 126; 129; 130). With this study we make three major contributions to the field. 
First, we identify that adipose-resident leukocytes, such as ATMs, remain elevated 
despite weight loss and retain their pro-inflammatory activation state. Second, we show 
that ATM accumulation and maintenance is not dependent on T or B cells, but these 
lymphocytes are required for maintenance of pro-inflammatory cytokine expression from 
ATMs after weight loss. Third, we show that eWAT tissue continues to develop 
structural abnormalities despite weight loss, including CLSs and fibrosis, without 
observed improvements in the expression of mature adipocyte-associated proteins like 
PPARγ and IRS-1. We conclude that obesity results in long-term alterations in mouse 
eWAT which fails to resolve despite extended time removed from HFD (Figure 5-1). 
Implications and future directions for these results will be discussed in greater detail 
below. 
 
Figure 5-1 – Development of features normally associated with chronically-obese adipose 
tissue in the eWAT of formerly obese mice. After weight loss, adipose tissue of formerly obese 
mice fails to return to a lean-like state (Left) and, instead, maintains or develops several features 
normally only associated with obese adipose tissue (Right). These features include crown-like 
structures, increased leukocyte accumulation, inflammatory activation of resident leukocytes, and 
impaired adipogenic protein expression profile.  
 
Maintenance of pro-inflammatory ATMs in eWAT despite weight loss 
The maintenance of activated pro-inflammatory leukocytes within adipose tissue 
after weight loss has important implications for obesity and immunometabolism research. 
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These findings challenge previously held assumptions regarding the status of adipose-
resident leukocytes in formerly obese subjects. We found that obesity can have a 
profound, potentially permanent, impact on the balance of leukocyte populations within 
adipose tissue. For example, the overall frequency of CD11c
+ 
ATMs climbs from ~20% 
in lean adipose to around 55%-60% during obesity. CD11c
+
 ATMs were retained at this 
frequency for as long as 6 months after HFD feeding had been terminated.  
The functional significance of macrophages in lean adipose tissue is still not 
completely understood. As research continues to shed light on the role that ATMs play in 
both lean and obese adipose tissue, it will be equally important to determine if ATMs are 
permanently changed by obesity or if they can still retain functional plasticity. If ATMs 
maintain polarization plasticity, then there is the possibility that adipose tissue leukocytes 
in formerly obese mice may be able to revert back and become “functionally equivalent” 
to those found in lean adipose tissue despite the differences in origin and surface marker 
expression. Unfortunately, we showed the ATMs in formerly obese eWAT still retained a 
highly pro-inflammatory expression profile suggesting they may not readily revert back. 
Even the CD11c
–
 ATMs developed a pro-inflammatory activation state which failed to 
resolve after weight loss. Overall, this indicates that ATMs are resistant to changing their 
polarization state once activated during obesity; our results would suggest this is 
particularly true in the presence of adaptive lymphocytes which will be discussed in 
greater detail below. More research would be needed to determine what other functional 
changes are induced by obesity and whether or not they revert after weight loss.  
 
The role of adaptive lymphocytes for maintaining inflammation after weight loss 
T lymphocytes have been shown to become activated in obese adipose tissue and 
are believed to play important roles in establishing inflammation (184; 232). 
Surprisingly, we found that T and B lymphocytes are not required for ATM recruitment 
and activation during obesity. However, these lymphocytes do seem to be required for 
maintenance of ATM pro-inflammatory polarization after weight loss. These findings 
suggest that B or, more likely, T lymphocytes potentially play important roles in 
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establishing and maintaining inflammation during obesity and weight loss. This also 
indicates there may be ways of ameliorating the pro-inflammatory activation state of 
ATMs after weight loss without depleting them. T lymphocyte expression of CD40L 
and/or IFNγ are interesting potential signaling mechanisms to explore for controlling 
activation of ATMs during obesity and weight loss. Deficiency in IFNγ has been shown 
to modestly improve insulin resistance and reduce adipose tissue inflammation in murine 
DIO models (111; 182). While pro-inflammatory ATMs have been associated with 
insulin resistance and adipose dysfunction, the mechanisms remain incompletely 
understood. As a result, even if the pro-inflammatory activation profile of ATMs could 
be reduced it remains to be determined if that would result in substantial health benefits 
or metabolic improvements.  
 
Continued development of eWAT structural derangements during weight loss 
We’ve observed that several features associated with obese eWAT become 
progressively worse with continual exposure to HFD. After 12 weeks of HFD, the eWAT 
depots are around their maximal size (~1.5g each), CLSs are present but relatively 
infrequent and fibrosis is minimal. After 20-25 weeks of HFD, the eWAT depots have 
begun to shrink, CLSs become numerous, and there is extensive tissue fibrosis which can 
be seen both micro- and macroscopically. One of the more surprising findings from this 
study was that removing HFD after 12 weeks of exposure still resulted in accumulated 
CLSs and extensive adipose tissue fibrosis. After weight loss, the eWAT looked 
histologically similar to adipose from mice exposed to HFD for a full 20 weeks. This 
shows that 12 weeks of diet exposure is sufficient to induce adipose tissue defects that we 
previously believed only occurred after long-term HFD exposure. Importantly, we also 
show that weight loss after less time spent on HFD, for instance 6 or 9 weeks, does not 
result in CLS and fibrosis accumulation. Somewhere between 9 and 12 weeks of HFD 
exposure a threshold seems to have been met. After this point has been reached, CD11c
+
 
ATM accumulation fails to reverse, CLSs will begin to accrue, and fibrosis will develop 
(Figure 5-2). This threshold is likely dependent on either adiposity gained or total time 
exposed to HFD. To my knowledge, there is no literature available to help narrow down 
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which is most likely responsible. However, I have observed that mice with malocclusion 
fail to develop body weight gains beyond 30-35g even with extended HFD exposure. 
Interestingly, the eWAT from HFD-fed mice with malocclusion does not develop or 
maintain the same features after weight loss as we observe in normal mice fed HFD for 
the same length of time. This would suggest that weight gain and/or total adiposity is 
more important than time spent on HFD before weight loss.  
Regardless, this concept of adiposity threshold limits has important implications 
for obesity and weight loss research. Definitions of obesity in mice are not nearly as 
clearly defined as they are in humans. While many recent manuscripts have only 
examined weight loss after mice have reached between 40g and 50g (51; 125; 130), some 
have studied obesity and weight loss in mice around 35g or less (112; 233). The findings 
from this dissertation would suggest that these differences in study design choice could 
have substantial impacts on the final results from, and conclusions reached by, different 
investigators. It would also be important to know if similar adiposity limits exist in 
human subjects which may affect the degree to which weight loss would be able to 




Figure 5-2 – Weight gained before weight loss influences maintenance of obesity-associated 
features in eWAT during weight loss. Weight loss in mice weighing around 35g allows better, 
though not perfect, recovery of eWAT tissue abnormalities including CLSs, CD11c
+
 ATM 
accumulation, and tissue fibrosis. Weight loss in mice weighing over 43g leads to the abnormal 
eWAT features we report on in chapter 3. 
 
An interesting open question is whether the pro-inflammatory ATMs remaining in 
formerly obese eWAT are directly responsible for encouraging continual adipose tissue 
derangement during weight loss. It’s possible, for example, that macrophages are simply 
responding to recruitment signals from adipocytes that are already dying or stressed as a 
result of obesity. We found that CLSs and tissue fibrosis still develop during weight loss 
in Rag1
–/–
 mice despite the substantially reduced inflammatory cytokine expression 
profile of ATMs from Rag1
–/–
 mice. Mature adipocyte-associated protein and gene 
expression from whole eWAT also remained altered in Rag1
–/–
 mice after weight loss. 
Overall, the results show that maintenance of inflammatory cytokine output from ATMs 
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is not required for the continual development of eWAT structural derangements observed 
during weight loss. Depletion of macrophages, through the use of clodronate-filled 
liposomes or diphtheria receptor expression systems, may allow us to determine if ATMs 
are responsible for ongoing adipose tissue derangement during weight loss. The work 
completed for this dissertation provides a way of evaluating whether adipose tissue can 
reacquire a lean-like profile during weight loss in the absence of ATMs. However, it’s 
important to keep in mind that ATMs may have beneficial roles within adipose tissue 
during both obesity and weight loss which remain incompletely understood. For example, 
it’s been suggested that ATMs may play important roles in extracellular matrix 
degradation and tissue remodeling in adipose tissue (234-236). In support of this, we 
showed that CD11c
+
 ATMs are still elevated in eWAT of WT mice even after six months 
removed from HFD, but there seems to be reduced numbers of CLSs in the eWAT of 
these mice. The CLSs still remaining also have substantial reductions in the surrounding 
extracellular matrix would could be the result of the retained ATMs. Additional research 
is still needed to understand if ATMs can help to maintain adipose tissue function and 
health.  
 
Additional general implications 
Obesity can alter basic physiology in a number of tissues aside from adipose and 
liver. Obesity is also associated with impaired bone integrity, pancreatitis, reduced lung 
function, and increased skeletal muscle inflammation (237-243). Adipose isn’t the only 
tissue that shows lasting changes after weight loss. Obesity can negatively impact bone 
health by increasing bone marrow adiposity, reducing trabecular bone volume, and 
reducing mineral content which results in deficient mechanical integrity and reduced 
fracture resistance. In 2016, we reported that femur trabecular bone volume and mineral 
content only partially recover after weight loss (244). As a result, the mechanical 
integrity and fracture resistance failed to recover after weight loss. We’ve also identified 
durable changes within the bone marrow hematopoietic progenitor pool, including 
increased myeloid progenitors, which is changed with DIO and remains altered even after 
serial bone marrow transplants into lean animals (154) or after weight loss (unpublished 
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findings). Within the pancreas, beta-cell mass increases during obesity to keep up with 
insulin secretion needs. Another research group found that beta-cell mass fails to be 
reduced after weight loss (125). It will be critical to investigate if weight loss is capable 
of fully resolving obesity-induced functional and inflammatory changes in other 
metabolically important tissues to gain a better understanding of how weight loss might 
impact metabolic health and whole body immune dynamics. 
 
Major additional future directions for chapter 3 
We were limited in the number of adipose tissue leukocyte populations that we 
could explore during weight loss due to time, expense, and the relatively low quantity of 
extractable leukocytes from a given mouse. T cells, macrophages, and dendritic cells 
were chosen based on their overwhelming presence in adipose and due to the field’s 
strong interest in these particular immune cells. However, several other leukocyte 
populations have been shown to play potentially critical roles in adipose tissue 
inflammatory responses during obesity and almost nothing is known about these cells 
during weight loss. NK cells, for example, can be important contributors of cytokines like 
IFNγ which can modify responses of other leukocytes such as ATMs. Adipose-resident 
NK cells are thought to increase during obesity and this cell population may play a 
critical role in establishing inflammation, but little is known regarding how this 
population is impacted during weight loss. It will be important to fully explore the 
potential changes that are induced by both obesity and weight loss in all major adipose-
resident leukocyte populations in both mice and humans. 
It would also be interesting to examine how weight loss induction through other 
mechanisms, such as caloric restriction with HFD or bariatric surgery, would compare 
with our diet-switch model. I have no reason to suspect that caloric restriction of HFD 
would improve the features we see maintained through diet-switch-induced weight loss, 
but it remains an interesting open question nevertheless. The Lumeng lab has ongoing 
collaborations investigating bariatric surgery in both mice and humans. Our unpublished 
findings, which are currently in peer review, suggest that bariatric surgery in mice may 
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alter the leukocyte composition after weight loss compared to the diet-switch based 
model used for this dissertation. For example, CD11c
–
 ATMs, rather than CD11c+ 
ATMs, and T cells seem to dominate in eWAT after bariatric surgery. We were only able 
to explore leukocyte population changes in these mice and have no information on their 
inflammatory potential. Further investigation of leukocyte activation and adipose tissue 
functional derangements, as explored in chapter 3, are still necessary to understand if 
bariatric surgery is more capable of resolving obesity-induced changes in mice. 
An additional major limitation within our study is the lack of data from human 
subjects. As discussed in the introduction chapter, murine gonadal adipose tissue is 
viewed as a rodent equivalent of human visceral omental tissue due to similarities in gene 
expression and inflammatory changes induced by obesity (23). Our results, derived from 
male gonadal white adipose tissue or eWAT, should help provide insight on potential 
expected outcomes during weight loss in human subjects regarding leukocyte changes 
and adipose tissue functional improvements. Schmitz et al. found that bariatric surgery 
failed to reduce omental ATM cell counts in approximately 41% of patients examined 
(125). Maintenance of omental ATMs in these patients was associated with increased 
inflammatory cytokine gene expression in adipose tissue and a failure to reduce CLSs 
one year after surgery. Adipocytes also maintained impaired insulin-stimulated glucose 
uptake in patients that did not have reduced omental ATM counts. The findings from this 
dissertation would suggest that ATMs in both patient subgroups may maintain their pro-
inflammatory polarization state, but individual ATMs were not evaluated by Schmitz et 
al. Additional gene and protein expression analysis of adipocytes from human subjects 
would be useful to determine how well bariatric surgery is capable of resolving obesity-
induced changes. 
 
Objectives, Major Findings, and Implications for Chapter 4 
The maintenance of features normally associated with chronic obesity in eWAT 
of formerly obese mice suggested the mice may also have persistent metabolic 
abnormalities. However, we found in chapter 3 that mice generally show improved 
metabolic function after weight loss including normal hepatic lipid involvement and 
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normal GTT/ITT responses. In chapter 4, we sought to determine if weight regain would 
reveal metabolic abnormalities that remain hidden while weight loss is maintained. We 
showed that eWAT tissue was incapable of properly expanding upon HFD re-challenge 
and secreted factors which inhibited in vitro adipogenesis of 3T3-L1 cells. We also 
showed that weight regain in formerly obese mice was associated with faster 
development of severe metabolic abnormalities, including hyperinsulinemia and hepatic 
steatosis, which we believe is linked to eWAT dysfunction (See model in Figure 5-3). We 
conclude that weight regain in formerly obese mice is associated with hastened 
development of metabolic abnormalities as a result of incomplete resolution of obesity-
induced features. Implications and future directions for these results will be discussed in 
greater detail below. 
 
Reduced expansion and lipid storage capacity of eWAT in formerly obese mice 
One of the primary functions of adipose tissue is the storage of excess caloric 
intake as energy-dense triglycerides for future use. Obesity encourages a dramatic 
hypertrophic effect in adipocytes, allowing individual adipocytes to greatly expand in 
size to accommodate increased storage demands (245). Proliferation and differentiation 
of adipocytes from the preadipocyte progenitor pool, also known as adipogenesis, is the 
other primary mechanism which helps increase the overall storage capacity of an adipose 
depot (205; 230; 246). The limited expansive capacity of eWAT during HFD re-
challenge suggests that obesity imparts major defects in one or both of these mechanisms. 
Adipocyte area was compared after weight gain in formerly obese and formerly lean mice 
revealing essentially identical adipocyte sizing curves. This indicates that individual 
adipocytes within formerly obese eWAT are as capable of storing triglyceride as 
adipocytes from eWAT of formerly lean mice. We believe that adipogenesis is impaired 
in formerly obese eWAT. As a result, there would be fewer functionally mature 
adipocytes within eWAT to store triglycerides which limits the overall lipid storage 
capacity of the entire depot. In support of this, proteins and genes critical for adipocyte 
differentiation and function are downregulated during obesity in whole eWAT and 
remain dysregulated despite weight loss. In addition, we found the preadipocyte 
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frequency in SVF from eWAT, but not iWAT, was increased by obesity and remained 
elevated despite weight loss which could be indicative of reduced differentiation 
efficiency in the preadipocyte population after weight loss. 
 
Unknown secreted factors from eWAT can directly inhibit in vitro adipogenesis 
We attempted to investigate potential mechanisms that may explain the limited 
expansive capacity of eWAT. We found that eWAT conditioned media from formerly 
obese mice, created from overnight culture of adipose tissue explants, was capable of 
inhibiting adipogenesis of 3T3-L1 cells. Reduced adipocyte protein expression and 
impaired adipogenesis has been linked to increased systemic insulin resistance in both 
mice and humans (247-251), and is also thought to be associated with ectopic lipid 
deposition during obesity (14; 247; 252). If these factors could be identified and 
neutralized, then eWAT lipid storage capacity could be restored in formerly obese mice 
potentially resulting in improved insulin sensitivity and reduced hepatic steatosis. 
Although we did not identify the factor(s) inhibiting adipogenesis in vitro, our studies 
effectively ruled out contribution of several putative cytokines and chemokines that 
might have been responsible. Several additional cytokines and signaling molecules 
remain to be investigated, and it’s entirely possible that the synergistic effects of multiple 
factors may be inhibiting adipogenesis. As a result, the identification and neutralization 
of the factor(s) responsible may be technically quite challenging.  
There may be additional derangements within eWAT that impairs expansion 
capacity in vivo during HFD re-challenge. One possibility is that the eWAT preadipocyte 
population is permanently impacted by obesity such that they’re no longer as capable of 
responding to differentiation cues. Primary preadipocytes from formerly obese and 
formerly lean mice could be tested in vitro to assess their differentiation responsiveness. 
However, primary preadipocytes from adipose tissue may not differentiate well in vitro 
unless conditions are optimized. In vivo lineage tracing of preadipocyte differentiation 
into mature adipocytes in formerly obese mice could provide a way around this problem. 
Unfortunately, several of the currently available models rely upon tamoxifen induction 
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which has been shown to directly induce adipogenesis and can continue to induce 
translocation of Cre-ER
T2
 in adipocytes for more than 2 months after treatment (253). It’s 
also unknown how weight loss and weight regain may modify tamoxifen’s action in 
preadipocytes. Known adipogenesis inhibitors, such as TNFα, could be tested in vitro to 
see if they impart durable changes in the differentiation efficiency of 3T3-L1 cells when 
treated several passages before initiating adipogenesis. If differentiation remains 
impaired, that would provide supporting evidence and reveal potential molecular 
mechanisms by which preadipocytes could be permanently changed during obesity in 
vivo. Careful study design and use of multiple models, including the ones above, will be 
necessary to determine the primary mechanisms responsible for limited eWAT expansion 
during HFD re-challenge.  
Despite not identifying the direct mechanism responsible, these data are still 
important for showing that obesity can impart changes in basic adipose tissue 
functionality, such as adipogenesis, which fails to recover despite a prolonged six-month 
removal from HFD. While weight regain has been previously linked to insulin resistance 
and increased adipose tissue inflammation (175; 203), to our knowledge, this is the first 
report showing altered adipose tissue expansion and functionality during HFD re-
challenge. Future research would be necessary to determine if the maintained 
inflammation within eWAT is linked to reduced depot expansive capacity. Regardless, 
identifying the primary mechanisms responsible will help pinpoint potentially targetable 
pathways for modifying adipocyte development and function in obese and formerly obese 
patients. 
 
HFD re-challenge of formerly obese mice leads to faster development of hepatic steatosis 
Knowing that eWAT tissue expansion and lipid storage capacity is impaired begs 
the question of where excess lipid ends up during HFD re-challenge of formerly obese 
mice. We found that hepatic steatosis and triglyceride content increases faster upon HFD 
challenge of formerly obese mice compared to formerly lean mice. Hepatic steatosis was 
associated with increased concentrations of transaminases in the serum which is 
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indicative of liver stress and damage. We propose a model wherein the preadipocytes 
found in formerly obese eWAT fail to differentiate into functionally mature adipocytes 
upon HFD re-challenge which results in increased ectopic lipid storage in organs such as 
liver (Figure 5-3). 
  
Figure 5-3 – Model showing failure of eWAT preadipocytes to properly respond to 
differentiation signals upon HFD re-challenge of formerly obese mice which leads to faster 
development of hepatic steatosis. Failed differentiation and maturation of adipocytes may be 
due to unknown factors directly inhibiting adipogenesis or intrinsic defects within preadipocytes 
imparted by previous obesity. Reduced fatty acid storage in eWAT results in increased ectopic 




Major additional future directions for chapter 4 
While we were able to identify failures in eWAT lipid storage capacity we were 
not able to test potential therapeutic solutions to correct this problem. If the lipid storage 
capacity or adipogenic potential of adipose tissue could be restored in formerly obese 
mice then the ectopic accumulation of lipid in tissues like liver may also be reduced. 
Identification of the primary mechanism(s) responsible for inhibiting eWAT expansion 
and adipogenesis would likely reveal the best potential therapeutic target, which is why 
we focused on this area of investigation, but the mechanism remains uncertain. 
Unfortunately, we also don’t have a way of specifically stimulating adipogenesis effects 
in adipose tissue without also affecting metabolism and lipid storage in other tissues. 
PPAR agonists, for example, can stimulate adipogenesis in preadipocytes (254), but these 
drugs also have systemic effects including increasing hepatic triglyceride storage (255). 
In general, the literature suggests that PPAR agonists tend to reduce DIO-induced 
steatohepatitis (256; 257), but the widespread effects could potentially confound results 
in our model. The adiponectin-overexpressing ob/ob model allows unrestricted adipose 
tissue expansion and is associated with substantially ameliorated hepatic steatosis (229). 
It would be interesting to see if this mechanism might work in our HFD re-challenge 
model. The use of adiponectin, either through overexpression or administration, might 
allow for better eWAT adipogenesis and lipid storage in these fat depots. Our model 
would suggest that increased lipid storage within adipose tissue should reduce hepatic 
steatosis, reduce serum transaminase concentrations, and may also reduce the 
hyperinsulinemia effect as well.  
Fatty acid uptake from the serum is believed to be the major contributor to 
accumulated liver triglycerides and a primary mechanism for hepatic steatosis in patients 
with NAFLD (258). However there are other potential sources of liver triglycerides 
which merit further discussion. The fatty acids taken up by liver can be derived from 
either dietary sources or from lipolysis of stored triglycerides within adipocytes. New 
fatty acids can also be created in liver through de novo lipogenesis from glucose stores. 
The evidence we’ve accumulated thus far suggests that fatty acid uptake, rather than 
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increased hepatic de novo lipogenesis, is responsible for the increased hepatic steatosis 
observed during HFD re-challenge of formerly obese mice. We found that liver genes 
critical for de novo lipogenesis are not elevated during HFD re-challenge of formerly 
obese versus formerly lean mice. In addition the literature suggests that de novo 
lipogenesis is a relatively small contributor towards hepatic triglyceride stores. Reduced 
triglyceride export from the liver and reduced fatty acid oxidation (or use) within the liver 
can also potentially contribute to increased hepatic steatosis. However, hepatic fatty acid 
oxidation rates and triglyceride export are not substantially reduced with NAFLD and 
obesity and in some studies may actually increase (218-222). Further intensive 
investigation would be necessary to definitively determine the degree to which each of 
these mechanisms might be involved for increasing hepatic triglyceride content. For 
example, isotope-labeled tracers would allow the relative sources (dietary, adipocyte 
lipolysis, or de novo lipogenesis) of hepatic triglycerides and fatty acids to be determined 
(214). It would also be ideal to perform hyperinsulinemic-euglycemic clamps during 
weight regain to better determine insulin action and glucose metabolism for the whole 
animal and individual tissues. These tests infuse mice with a constant physiologically-
high concentration of insulin while providing variable glucose infusion which can also be 
labeled for tracing (259; 260). This is viewed as the gold standard for evaluating tissue 
sensitivity to insulin and, if using labeled glucose, allows relative glucose utilization in 
metabolically important tissues to be evaluated as well. The combination of isotope 
labeled fatty acid tracing and hyperinsulinemic clamp studies would allow for better 
assessment of metabolic health in HFD re-challenged mice. The number of mice and time 
required for these studies prevented us from exploring them further, but they would be 




The findings from this dissertation challenge previously held assumptions 
regarding adipose tissue inflammatory and functional recovery after weight loss. We 
found that while weight loss can improve metabolic function, it’s still an imperfect 
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resolution of the changes imparted by obesity. As a result, HFD re-challenge of formerly 
obese mice led to the development of metabolic abnormalities including 
hyperinsulinemia, adipose tissue functional derangement, hepatic steatosis, and hepatic 
damage.  
These results still leave open the question of what role leukocyte activation and 
adipose tissue inflammation plays in adipose tissue dysfunction and insulin resistance 
during weight loss and weight regain. While our studies were not designed to answer this 
question, it’s still central to our motivation for investigating how adipose-resident 
leukocytes are altered during weight cycling. Given the preponderance of literature 
associating adipose tissue inflammation with systemic insulin resistance, we would 
hypothesize that failure to fully resolve leukocyte activation state during weight loss 
would result in more severe insulin resistance than what was observed in chapter 3. The 
Rag1
–/–
 experiments also showed that inflammatory cytokine production from ATMs is 
not necessary for maintaining insulin resistance after weight loss. If inflammatory 
cytokines do normally play a critical role in establishing insulin resistance during obesity, 
then it’s possible that the overall inflammatory cytokine output of adipose tissue is 
reduced enough during weight loss that systemic insulin sensitivity can largely recover. 
This would fit with previous publications reporting reduced circulating inflammatory 
cytokine expression, and reduced insulin resistance, during weight loss (261; 262). HFD 
re-challenge of formerly obese mice, compared to formerly lean mice, led to faster 
accumulation of ATMs and T lymphocytes in eWAT and increased TNFα expression. 
The hyperinsulinemic effect observed in HFD re-challenged mice may be due to this 
increased inflammatory activity within adipose tissue, but the concomitant development 
of other features during re-challenge, most notably hepatic steatosis, may also influence 
insulin resistance in these mice. Separating recruitment and activation of adipose tissue 
leukocytes from hepatic steatosis during HFD challenge is difficult. If we could identify a 
way of restoring eWAT expansive capacity in formerly obese mice then it may be 
possible to reduce hepatic steatosis while preserving leukocyte accumulation in adipose 
tissue. Otherwise depletion studies, for instance clodronate-filled liposomes, could be 
used during HFD re-challenge to reduce ATMs after which systemic and local 
metabolism could be analyzed. Treatment with anti-inflammatory cytokines (IL-10), or 
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treatment with neutralizing antibodies to reduce available inflammatory cytokines, could 
also be useful for determining the role of inflammation in metabolic dysregulation during 
HFD re-challenge of formerly obese mice.  
Overall, the results suggest that health complications associated with weight gain 
may be variable depending on prior obesity status and metabolic impairments. It’s crucial 
to mention that this should not be construed as indicating that weight regain and/or 
weight cycling is worse than maintained obesity. While not tested directly, it’s likely that 
long-term HFD challenge of formerly obese and formerly lean mice, leading to body 
weight and adiposity stabilization, would result in similar metabolic derangements and 
hepatic steatosis between these two groups. Regardless, it’s important to know if even 
small weight regain in formerly obese subjects may result in hastened development of 
severe metabolic consequences. We hope these studies will promote renewed research 
interest in identifying ways of better resolving obesity-induced effects during and after 
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